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Background and objectives: Inclusion body myositis (IBM) is an inflammatory myopathy that 
frequently affects patients over 45, causing atrophy and weakness in proximal and distal 
muscles. The muscle histology is characterized by the infiltration of T cells, that direct responses 
against muscle leading to their destruction. T cells responding to single or common antigens will 
consist of monoclonal or oligoclonal populations respectively. Previous studies have sequenced 
the receptor of infiltrating T cell populations and found evidence of clonal (TCR) restriction. 
Furthermore, expansion of rare T cells which includes CD8+ T cell large granular lymphocytes 
(TLGL) and gamma-delta (γδ) T cells, are increasing in IBM patients. T-LGL expansion is a 
precursor of T-LGL leukaemia and presents an additional burden for IBM patients. γδ-T cells 
constitute an unconventional T cell subset whose functions include anti-microbial and anti-
tumor immunity. We aim to confirm if 1) if T-LGL leukaemia is associated with IBM and if we can 
distinguish these T-LGL on the basis of phenotype 2) if γδ-T cells with alterations in their 
repertoire are expanded in IBM patients and 3) determine the clonal diversity of T cells in 
peripheral blood and muscle.  
Methods: Twenty-five IBM patients (Male =10, Female=15, mean age=73) and seventeen 
healthy controls (Male =10, Female=7, mean age=65) were recruited through the institute for 
immunology and infectious disease (IIID), Murdoch University. Blood samples were collected and 
analysed using flow cytometry. Additionally, muscle biopsies and PBMCs were taken from two 
IBM patients were analysed via bulk Next Generation TCR sequencing.  
Results: T-LGLs are late-differentiated cells that display a characteristic CD8+ CD57+, CD5-, 
KLRG1+, and variable expression of CD94+, and CD56+ phenotype. 8/25 (32%) of IBM patients 
showed expansion of T-LGL compared to 17% of healthy controls (H.C). The proliferation of 
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CD5CD57 populations was assessed using ki67. Overall, these populations’ proliferation 
potential was reduced; however IBM + T-LGL patients show a slightly higher frequency of ki67 
than IBM T-LGL- and HC.   
Increased frequency of γδ T cells (>4% of total T cells) is observed in 27% of IBM patients 
compared to 7% of H.C. The proportion of Vδ1 T cells is slightly greater than Vδ2 T cells, yet is 
seen in both IBM and H.C  The Vδ1 subset in IBM and H.C display higher proportion of TEMRA cells 
that show reduced expression of Ki67 yet show higher frequency of CD27- and variable 
expression of CX3CR1 and CD57. The Vδ2 cell has a higher proportion of TEM and has slightly 
higher expression of Ki67 and displays the highest frequencies of CX3CR1 yet CD57 frequency 
was variable. Frequency of Vδ2 CD27+ was highest in IBM patients compared to healthy controls.  
Lastly, the TCR sequence analysis of peripheral blood CD4 and CD8 and muscle homogenate 
reveals common TCRβV and TCRβJ rearrangements and CDR3 sequences and/or terminal motifs 
across the three samples and between the two IBM donors.  
Conclusions: We found evidence of two populations of rare T cells expanding in IBM patients; 
however, we also see a considerable portion of healthy controls with the same phenotypic 
changes proposing that these changes are due to the effects of ageing. TCR sequences analysis 
indicates an oligoclonal repertoire with a few common sequences found between IBM patients 
suggesting an immunogenic response directed towards common antigen(s).  
Keywords: Inclusion Body Myositis, Large granular Lymphocytic leukaemia, gamma-delta T cells, 
lymphocytes, autoimmune disease, chronic inflammation, ageing, TCR sequencing, Next 
Generation Sequencing, clonality, monoclonal, oligoclonal, polyclonal.  
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Chapter 1: Literature Review  
1.0 Introduction  
Inclusion body myositis is a progressive inflammatory myopathy and the most frequent 
inflammatory myopathy in patients over the age of 45.(1, 2)  IBM is an asymmetric condition, 
affecting proximal and distal muscle groups, such as the quadriceps tibialis anterior, finger and 
forearm flexors; and at advanced stages of the disease, pharyngeal muscles are affected, leading 
to dysphasia.(3) The etiology of IBM is poorly understood, but current theories suggest that both 
inflammatory and degenerative processes are contributing to the disease progression and 
symptom manifestations.(4, 5) It is, however, heavily debated as to whether degenerative changes 
precede inflammatory changes or vice versa.(6) Histologically, IBM muscle fibers reveal 
degenerative changes, such as 15-18nm filamentous inclusions and the presence of β-amyloid 
that disrupt normal cellular processes.(3, 4) The inflammatory changes include endomysial 
infiltrates, dominated by CD8+ cytotoxic T cells and macrophages, which invade nonnecrotic 
muscle fibers overexpressing the major histocompatibility complex- I (MHC-I).(4) Emerging 
evidence, has revealed IBM as an autoimmune disease, based in part to associations with 
myositis specific autoantibodies (CN1A), production of Th1-mediated cytokines, overproduction 
of MHC-I and associations with HLA alleles.(7) However, classically prescribed 
immunosuppressive therapies are ineffective against IBM, thus at present, no adequate 
treatment option is available.(2, 8) It is for this reason as to why further investigations into the 
underlying pathological mechanisms of IBM is crucial as the foundation of our understanding of 
this disease. 
This review will provide a general overview of the diagnostic criteria and epidemiology of 
inclusion body myositis, as well as discuss current theories into the pathophysiology, including 
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degenerative and inflammatory related changes. We shall also discuss how T-lymphocytes 
develop into their respective CD8+ and CD4+ lineages the structure of the T cell-receptor found 
on these T cells and how dysregulation in these lineages can promote autoimmune responses. 
The focus of this review concerns the clonality of the T cells within IBM patients in addition to 
two rare and under-reported populations of T cells: γδ T cells and T cell large granular 
lymphocytes (T-LGL). Better characterization into the immunobiology of the T cell populations 
may provide greater insights into the underlying pathomechanisms of this disease. 
1.1 Diagnostic Criteria for IBM 
Inclusion body myositis was first defined in 1971 by Yunis and Samaha after a histological sample 
taken from a myopathy case revealed the presence of “inclusion bodies” (i.e. protein-filled 
vacuoles) within the muscle fibers.(9) Over the years, several more cases were identified, 
presenting with specifically distinct pathological and clinical characteristics that were unique 
from other inflammatory myopathies. Inclusion body myositis was characterized diagnostically 
in the 1990s and by 1995 the proposed diagnostic criteria known as the “Griggs criteria” was 
established.(3, 10) According to the Griggs criteria, a conclusive diagnosis three characteristic 
pathological features including the presence of protein inclusions within the muscle fibers 
(consisting of β-amyloid), or 15-18nm tubulofilaments;  in addition to the presence of rimmed 
vacuoles and endomysial infiltrates of CD8+ cytotoxic T cell and macrophages.(10) Laboratory 
findings such as an increase in creatinine kinase (12x normal) may also be useful for diagnostic 
confirmation. However, clinical features are not necessary for a definitive diagnosis(10). 
Additionally, the Griggs criteria offers that a possible diagnosis is considered if partial 
pathological findings are present in addition to clinical features such as a duration >6month, the 
age of onset is > 30 years and at least one of the following: weaknesses in finger flexor, weakness 
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of wrist flexors > wrist extensor and/or quadriceps weakness.(10) In more recent years, it has been 
identified that the Griggs criteria may not be the most accurate method for classifying IBM.(11) 
For instance, the histological findings may not always be present for patients with the typical 
clinical features of IBM.(12) In response to this, amendments to the Griggs criteria were elicited 
to form a new criterion, the European Neuromuscular Centre (ENMC) diagnostic criteria.(11) This 
criterion now includes a new antibody known as anti-cytosolic 5 nucleosidase 1A (cN1A) and is 
now the more favoured criteria for diagnosing IBM.(11, 12)  
1.2 Epidemiology of Inclusion Body Myositis   
Epidemiological studies for IBM have revealed a varying degree of differences between ethnic 
groups and countries, though this disease may be significantly underreported, due to delayed 
diagnoses, given that the symptoms are relatively non-specific without invasive muscle biopsies. 
For instance, a survey conducted in Western Australia in the early 2000s initially reported the 
prevalence of IBM to be 9.3 cases per million, but in 2008 it was later revised and updated to 
14.9 per million population. (13) In South Australia, the prevalence was reported to be much 
higher at 50.5 per million population in 2013. (14) Similarly, among other westernized countries 
the prevalence varies substantially from 10.7 per million population in Connecticut, USA,(15) to 
70.6 per million in Minnesota.(16) Two studies conducted in Europe found that the prevalence of 
IBM in the Netherlands was roughly 4.3 per million, whereas in Norway, reported 33 cases per 
million.(17, 18) Few studies have been undertaken amongst Asian countries, although in Japan, IBM 
is shown to have increased over the years. In 1991, the prevalence was estimated to be 1.28 per 
million, whereas in 2003, the prevalence rose to an estimated 9.83 per million.(19) Based on these 
population studies, the prevalence of IBM classifies this disease as rare although the increasing 
prevalence documented throughout  may be due to greater methods of diagnosis.    
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1.3 The Degenerative Changes within IBM 
A constant theme presented throughout the literature is the deciphering argument as to 
whether the pathogenesis of inclusion body myositis is primarily an inflammatory myopathy with 
myofiber degeneration or a degenerative myopathy with reactive inflammation. This argument 
has been likened to the philosophical “chicken or the egg” debate.(6) The argument in favour of 
it being a degenerative process stems from the fact that IBM is typically resistant to current 
immunosuppressive therapy. Multiple studies have demonstrated the ineffectiveness of 
immunosuppressants and/ immune-modulating therapies such as methotrexate and 
intravenous immunoglobulins (IVIg).(2, 8) However, in one study, intravenous immunoglobulins 
(IVIg) was used in the treatment of four IBM patients with severe dysphagia and was shown to 
improve symptoms dramatically.(8)  Nonetheless, the use of immunosuppressants for the 
treatment of IBM appears redundant, and this may favour the argument that IBM is primarily a 
degenerative disease. Irrespective of this, other diseases of autoimmune origin, such as 
scleroderma and the progressive form of multiple sclerosis have been documented to be 
refractory to immune-modulating treatments.(6) 
 Another theory in support of IBM being a primary degenerative disorder has been the 
accumulation of intracellular deposits of proteins such as amyloid β into vacuolated inclusions 
within muscle fibers.(3, 20-22) Pathological accumulations of β-amyloid have also been identified to 
accumulate in certain neurodegenerative disorders such as Alzheimer’s disease and Down 
syndrome.(23) It is, however, still debated as to whether accumulations of β-amyloid ultimately 
lead to cellular degeneration or if the degeneration itself is responsible for the accumulation of 
β-amyloid.  Accumulation of β-Amyloid precursor protein (βAPP) more specifically Aβ40 and 
Aβ42 are shown to be increased in plasma blood samples taken from IBM patients compared 
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to other inflammatory myopathies (polymyositis and dermatomyositis) and healthy control 
subjects.(20) The pathophysiological relevance of increased accumulation of amyloid β protein 
requires further investigation; however β-Amyloid has been demonstrated to induce cytotoxic 
functions within muscle fibers or cause disruptions to intracellular muscle calcium 
concentrations.(24, 25) Muscle weakness is a common clinical feature of IBM, and may, 
therefore, stem to reason that the process of force production that governs muscle 
contraction could be affected. Several authors have previously reported that as intracellular 
β-amyloid levels accumulate within the myofibers of skeletal muscle, the levels of myoplasmic 
Ca2+ also increases.(25-27) Increases in calcium ions are responsible for hyperpolarizing a cell, 
meaning that a greater action potential is required for muscle contraction.(28) Therefore, 
disruption in the intracellular concentrations of Ca2+ might explain the progressive muscle 
weakness seen in IBM patients.  
Although there is a convincing amount of evidence in favour of degenerative mechanisms (such 
as increased protein aggregated) considerably affecting myoproteostasis, the exact mechanism 
by which β-amyloid accumulates within the myofibers is still to be determined. One such theory 
involves disruptions during autophagy, which is the process of removing accumulated cellular 
debris. During this process, debris such as aggregated proteins and damaged organelles are 
engulfed by a vesicle, known as an autophagosome.(29) These autophagosomes fuse to 
lysosomes, and the debris is then degraded.(29) Failure during autophagy will, therefore, result in 
the accumulation of the debris.(6) In relation to IBM, the inability of skeletal muscle to remove β-
amyloid could, therefore, result in its accumulation. One study by Lünemann et al. (2007),(30) 
found that β-amyloid and its precursor proteins were increased in autophagosomes of IBM 
muscle fibers compared to controls. They demonstrated that β-amyloid is a target for 
autophagosomal activity, while another study, reveled lysosomal enzyme activity was 
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significantly decreased in skeletal muscle of IBM patients.(31) Thus, it can be concluded that the 
skeletal muscle cells can autophagocytose β-amyloid, but they are unable to initiate degradation, 
resulting in its accumulation.(31)  
1.4 The Immunological Changes Within IBM 
The second theory into the pathoetiology of IBM concerns inflammatory related changes 
observed within the muscle fibers. CD8+ T cells and macrophages are the dominant inflammatory 
infiltrates though to a lesser degree CD4+, and B cells are known to invade non-necrotic muscle 
fibers overexpressing MCH-I.(3, 4, 6) Here, we describe the development and functions of the two 
T cell entities: CD4 and CD8 cells; to provide a contextual insight into how these cells relate to 
the development of autoimmune diseases and investigate how dysfunctional changes observed 
within these T cell lineages reflect the immunological changes seen in IBM. Furthermore, 
expansion of rare T cell populations including gamma-delta (γδ) T cells T-cell large granular 
lymphocytes (T-LGLs) have recently been observed to be increasing in IBM patients. The role of 
these T cell populations is poorly characterized in the context of IBM, though they too have been 
associated with autoimmunity and are nonetheless important within the pathoetiology of this 
disease.  
1.4.1 The Development of Autoimmunity 
Autoimmunity and autoimmune diseases are described as the inappropriate response of 
immune cells recognizing self-antigens as foreign.(32) Self-antigens, generally termed 
autoantigens do not normally provoke an immune response due to mechanisms of immune-
tolerance, which includes central and peripheral tolerance.(32) Central tolerance involves the 
development of T lymphocytes and the education of these cells to distinguish self from non-self-
antigens, whereas peripheral tolerance works to sustain immunotolerance and 
Page | 18  
 
immunosuppression.(33) Dysregulation in the processes that govern central and peripheral 
tolerance has been linked to the development and promotion towards autoimmune diseases, 
although like many chronic conditions multiple influences including genetic and environmental 
factors are linked to increased susceptibility.(34) Importantly, autoimmune diseases aren’t limited 
to the T cell lineage and that dysfunction within  B cells can also result in an autoreactive 
response.(32, 35) However, for simplicity we will focus on dysregulation in systems involving T cell 
lineages.   
Autoimmune diseases can arise in an organ-specific or systemic manner.(34, 35) As the name 
suggests, organ-specific autoimmune diseases result from immune cells inappropriately 
responding to an antigen-specific to a single tissue/organ.(32, 34, 35) Conversely, systemic 
autoimmune diseases, generally arise in response to an immune attack against self-antigens 
common to multiple organ systems,(34) for example, rheumatological disorders can affect 
epithelium, joints, muscle and kidney regions.(32) Another feature common in autoimmunity is 
the incidence of multiple autoimmune diseases occurring together. For instance, autoimmune 
rheumatic diseases such as systemic lupus erythematosus (SLE), scleroderma, and myositis tend 
to overlap with one another.(32) Similarly, observations of IBM patients has revealed associations 
with other autoimmune conditions, including Sjogren’s syndrome, autoimmune thyroiditis and 
rheumatoid arthritis.(6, 36)  
Studies involving the association amidst certain autoimmune diseases and the host genetics have 
revealed that certain haplotypes of the human leukocyte antigen (HLA) have been linked with 
increased susceptibility of acquiring an autoimmune disorder.(32) The human leukocyte antigen 
encodes for a particular region within the Major histocompatibility complex (MHC), which is the 
primary molecule for presenting antigens to immune cells.(32) HLA associations are implicated in 
many different autoimmune conditions, for example, HLA-B27 and HLA-DR15 are known to be 
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susceptible genes for the development of ankylosing spondylitis, and multiple sclerosis 
respectively. Similarly, recent investigations have identified that IBM is strongly associated with 
the HLA-DR3 and the MHC 8.1 ancestral haplotype.(37, 38)  Taken together, we can appreciate how 
features common to autoimmune diseases overlap with those seen in IBM.  
1.4.2 T cell Development and Differentiation into CD4+ and CD8+ Lineages: 
A critical function of immune cells is their ability to detect foreign molecules and proteins but 
tolerate self-proteins.(39) The processes of central and peripheral tolerance are the main 
mechanisms of how adaptive immune cells are submitted to tolerance.(35, 39) Dysregulation in 
these processes can result in complications within the immune responses and may result in the 
development of autoimmunity.(39) Appreciation for how immune-related diseases occur can 
stem from our understanding of how T cell lineages arise.  
T cell ontogeny begins with lymphoid progenitor cells migrating from the bone marrow into the 
thymus. Here, the process of central tolerance occurs whereby T cells undergo a series of 
differentiation stages to establish antigen specificity.(32, 33) A vast number of antigenic epitopes 
are recognizable by the T cell population and is mediated through the T cell receptor (TCR). 
Initially, immature thymocytes are termed double negative (DN) indicating that they express 
neither of the cluster of differentiation (CD) co-receptors (CD8 or CD4). As DN thymocytes 
proceed along their maturation pathway, T cell receptor genes segments termed variable (V), 
diversified (D) and joining (J) undergo somatic cell recombination via the recombination-
activating gene enzymes (RAG1 and RAG2).(32, 33) The product of which, is a receptor known as a 
T cell receptor (TCR) and comprises of either γδ or αβ subunits. The mechanism related to γδ 
TCR selection is still largely unknown, and it is thought that after generation of the γδ TCR the 
cells exit the thymus and emigrate into the periphery.(32) Lymphocytes proceeding along the αβ 
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pathway begin to express both co-receptors (CD8 and CD4) and is now referred to as being 
double-positive (DP).(33) In order for these DP cells to commit to a particular lineage (i.e. become 
CD8+ or CD4+), they undergo a selection process characterized by four stages- Positive selection, 
negative selection, lineage -specific development or death by neglect.(33) Death by neglect simply 
occurs due to inadequate TCR and/or co-receptor signaling, thereby disallowing the cell to 
continue along its differentiation pathway.(33) Positive selection dictates that lymphocytes are 
capable of interacting to antigens presented via the major histocompatibility complex (MHC- 
class I binds to CD8+ or MHC-II binds to CD4+molecules).  Lymphocytes with moderate affinity for 
their corresponding MHC molecule will be positively selected. Negative selection, by contrast, 
occurs when T cells expressing TCRs with high affinity for self-peptides are depleted by 
apoptosis.(35, 40) Double positive cells that survive the positive and negative selection processes 
will begin to commit to a particular lineage by downregulating and eventually diminishing one 
of the CD molecules to become a single positive (SP) cell.(33) SP cells then emigrate from the 
thymus into the periphery where they await subsequent antigenic stimulation.(33)   
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Figure 1: Schematic Representation of Central Tolerance Theory. Double negative cells (DN) 
undergo somatic cell recombination via RAG1/RAG2 proteins to develop a T cell receptor (αβ or 
γδ TCR). Lymphocyte expresses both co-receptor molecules CD4 and CD8 and are referred to as 
double-positive cells (DP). Double positive cells recognize major histocompatibility complex 
(MHC) corresponding to the appropriate CD molecule (MHC-I binds to CD8/ MHC-II binds to 
CD4). Cells with moderate affinity for MHC will be positively selected. Cells with high or low 
affinity will undergo death by neglect. DP cells experience negative selection, whereby self-
peptides are presented to the cell. If the DP cell recognizes these peptides with high affinity, 
then the cells will die through apoptosis. DP cells with low affinity for self-peptides will commit 
to a particular lineage (i.e., become single-positive (SP) for CD4 or CD8).  Adapted from Germain 
RN, 2002(33)  
1.4.3 The Structure of the T cell Receptor  
The T cell receptor (TCR) is an integral membrane protein consisting of two polypeptide chains 
with either γδ or αβ subunits (figure 2a).(32, 41) These receptors are associated with a collective of 
cytoplasmic and membrane-bound proteins that make up the CD3.(41) This CD3 molecule is a 
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marker for all T cells of both γδ and αβ lineages.(32) T cell receptors with assistance from co-
stimulatory molecules (CD8 or CD4) recognize and respond to antigens with a high degree of 
specificity.(41) These co-stimulatory molecules are additional identifiers for certain T cell 
subtypes; for instance, the majority of T regulatory and T helper cells are designated as CD4+ 
whereas,  the majority of cytotoxic T cells are designated as CD8+.(32) The distinction of which 
becomes evident later on, although exceptions are known (some CD8+ T cells show T regulatory 
and helper roles and some CD4+ cells have cytotoxic functions). The extracellular portion of the 
TCR consist of a constant (C) and a variable (V) domains(41-43) (figure 2a). The Variable domains 
are of high importance as they contain the hypervariable region known as the complementary 
determining region 3 (CDR3) and is the portion of TCR binding site that interacts with an antigenic 
peptide (32, 42) (figure 2B). Once stimulated, a T cell will proliferate generating a vast number of 
cells with identical specificity and capabilities of producing effector functions (i.e. production of 
cytokines and cytotoxicity).(32) 
1.4.4 T cell receptor genes and Clonality   
The genes that encode the TCR are located on chromosome 7 (TCRβ and TCRγ genes) and 
chromosome 14 (TCRα and TCRδ genes).(42, 44) The germline organization of the T cell receptor 
genes are categorized into variable (V), joining (J), and constant (C) segments.  Moreover, TCRβ 
and TCRδ contain an additional segment known as the diversified (D) segment and contributes 
to the diversity within these receptors(42) (figure 2c). Each of the TCRs vary in V (D) J and C 
segment numbers and families that collectively designate the four α,β,γ, δ TCR genes into the 
World Health Organization standards for TCR nomenclature and is shown in Table 1. 
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As discussed previously, these TCRs undergo somatic rearrangements of the V, (D), and J gene 
segments resulting in enormous amounts of different sequence combinations within the CDR3 
portion of the TCR (figure 2B). Sequencing the composition of the T cell receptor is typically seen 
for TCRβ or TCRδ as these two contain the diversified (D) segments.(44) Sequencing also 
characterizes the TCRs diversity and thereby determines if the T cell population observed is 
responding to a single antigen (monoclonal T cell expansion), few antigens (oligoclonal) or 







Figure 2: Schematic representation of the T cell Receptor structure. A) T cell Receptor (TCR) 
containing a constant and variable domain B) detailed regions of the TCR showing the different 
segments of the TCR C) close up view of the CDR3 region comprising of the different V, D, J genes.  
Adapted from Tiago M, et al. 2017(43) and  Hodges E, et al. 2003(42)  
Table 1 Adapted from Rubinstein et al44  
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1.4.5 Peripheral Tolerance and the Role of Regulatory and Helper T cells  
Even if self-reactive T cells manage to escape the processes of central tolerance and reach the 
periphery, several additional mechanisms exist within the periphery to avoid self-reactive T cells 
from having deleterious effects.”(32)  This process, referred to as “peripheral tolerance is 
maintained through several mechanisms including deletion by apoptosis, induction of anergy 
and development of induced T regulatory cells (iTregs).(32)  Peripheral deletion by apoptosis 
(programmed cell death) reinforces self-tolerance and helps to maintain immune- homeostasis 
through the removal of self-reactive T cells that have escaped thymic deletion and thereby aid 
in avoiding autoimmunity.(32)  Moreover, T cells that remain inactive upon recognition of cognate 
antigen are termed anergic;(32) and are an effective mechanism in response to superantigens or 
prolonged exposure to antigen.(32) However, T cell anergy can be revised in vitro through 
exposure to IL-2.(32)   
Additionally, several other mechanisms also play a role in avoiding autoreactive T cells such as 
Immunological ignorance, which is achieved as long as self-reactive T cells avoid their cognate 
autoantigen.(32) This process is generally through immunologically privileged tissues whereby 
anatomical barriers prevent migration of lymphocytes into these tissues e.g. blood-brain barrier.  
Another critical component of T cell immunotolerance are regulatory T cells (Tregs). These are a 
distinct subset of CD4+ T cells, specialised in maintaining tolerance to self-antigens, in addition 
to suppressing excessive immune responses.(45) Immunotolerance and immunosuppression are 
important processes for sustaining homeostasis within the immune system, and dysregulation 
within Tregs have been linked to autoimmunity.(46, 47) Tregs that develop during thymic selection 
are termed “natural Treg cells,” however, T cells may also acquire Treg phenotypes and functions 
in the periphery and are referred to as “induced Tregs.”(32)  These iTregs are of particular 
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importance in tissues such as the intestines, where T cells are subjected to continuous antigen 
stimulation from microbes.(32) Tregs are identified by expression of cell surface markers CD25, 
CD127, and the transcription factor FOXP3.(46-48) CD25 is the α chain of interleukin-2 (IL-2) 
receptor, and functions as a T-cell growth factor receptor.(48)  CD127 is the marker for the α chain 
of interleukin-7 receptor (IL-7) and is useful for identifying activated Tregs, as these cells are 
reported to be CD127low which is valuable for discriminating from naïve T-helper cells which are 
CD127 high.(48) Expression of the transcription factor FOXP3 was a major discovery for studies into 
autoimmune diseases and is described as the principal regulator for the development and 
functionality of Tregs.(46, 47)  For example, mutations within FOXP3 have been demonstrated to 
induce autoimmunity in mouse models and is responsible for immune dysregulation, 
polyendocrinopathy, enteropathy, X-linked (IPEX) syndrome in humans. (32, 46, 47) 
T regulatory cells have been associated with many autoimmune conditions such as psoriasis and 
systemic lupus erythematosus (SLE) which has revealed that a decrease in the number or the 
function of these cells is related to increased disease severity and poorer prognosis.(49) (iTregs). 
In a study performed by Allenbach et al(46) The expression of CD45RA was used to distinguish 
between natural Tregs (CD3+, CD4+, CD25+, CD45RA-, FOXP3+), activated Tregs (CD3+, CD4+, 
CD25+, CD45RA-, FOXP3high) and resting Tregs (CD3+, CD4+, CD25+, CD45RA+, FOXP3+).(46) In IBM 
patients, it has been shown that there is a lower percentage of natural and activated Tregs 
compared to healthy controls, yet the difference in resting Tregs was insignificant between IBM 
and healthy controls.(46) Decreases in Tregs frequency have been observed in autoimmune 
diseases,(49, 50) as well as other myopathies such as dermatomyositis and polymyositis.(50, 51) This 
suggests that decreases in Treg frequency are not unique to IBM but that their abundance and 
function does play a critical role in this disease, and warrants further exploration.  
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Helper T cells (Th) is another population of CD4+ cells whose functions play an important role in 
promoting immune responses through the production of inflammatory cytokines and 
chemokines.(46, 52) During CD4 development, environmental circumstances promote the 
secretion of cytokines which aids in polarizing naïve T helper cells (Th0) into their perspective T 
Helper cells lineages Th1 and Th2 and Th17 (52) The role of  CD4+ T cells is associated with the 
pathogenesis of chronic inflammatory and autoimmune conditions including diabetes and 
rheumatoid arthritis.(52)  T helper cells, more specifically, the Th1 lineage has been investigated 
in IBM, where the production of inflammatory cytokines such as IL-2 and IFN-γ as well as 
chemokines such as CXCL-9 and CXCL-10 were revealed to be increased.(46) The two chemokines 
(CXCL-9 and CXCL-10) secreted by Th1 cells promote CD8+ T-cell effector memory (TEM) migration 
to inflamed tissues.(46) The abundance of these chemokines, as well as increased production of 
IL-2 and IFN-y cytokines in IBM, indicate a Th1 mediated response is associated with IBM 
patients.(7)   
 
1.4.6 The Role of the cytotoxic T cells  
The CD8+ lineage that arises from lymphocyte development produces cells whose primary 
function is cytotoxicity (cell-killing). Histologically, IBM muscle fibers demonstrate invading 
lymphocytes that are dominated by cytotoxic T cells (CD8+) and macrophages.(3, 4, 6) Muscle 
lesions not only become inundated by inflammatory infiltrates but have been shown to 
upregulate MHC-I. (4) Generally, MHC-I expression is undetectable in muscle fibers; however, in 
IBM, the abundance of MHC-I suggests that the muscle may act as antigen presenters and 
therefore become targets for autoreactive T cells.(4) Activated CD8+ cells are highly cytotoxic, 
through the release of cytolytic proteins, such as perforin, granulysin, and granzymes that 
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ultimately lead to cell death (apoptosis).(53) Such molecules have been shown to be increased in 
IBM patients.(54)  
1.4.7 Clonality of Muscle infiltrating T cells in IBM 
A study performed by Bender et al(55) described the clonal difference between T cells that invade 
IBM muscle fibers referred to as autoinvasive T cells, and T cells that do not invade the muscle 
fibers, but rather surround the fibers termed interstitial T cells.(55) The authors combined 
immunohistochemistry with TCR Vβ family-specific monoclonal antibodies (mAbs) and reverse 
transcription polymerase chain reaction (RT-PCR) with Vβ-family specific oligonucleotide 
primers.(55) The clonal differences between the two populations of T cells identified that the 
autoinvasive T cells were oligoclonal or monoclonal, whereas interstitial T cells were mostly 
polyclonal (Figure 3 A).(55) Muscle samples were taken from three IBM patients and analyzed 
through TCR sequence analysis to determine the variable region of the β-chain (Vβ family). In 
one patient, the TCR Vβ5 family was amplified and found that autoinvasive T cells for CD8+ Vβ5.3 
were clonally restricted, whereas populations of interstitial T cells for CD8- VB5.1 were clonally 
diverse.(55) Though the results seem to suggest a conclusion of a clonally restricted vs. clonally 
diverse phenotype between the two populations, it should be noted that the techniques used in 
this study have considerable limitations. 1) the panel of anti-TCR Vβ mAbs were only able to 
detect about 50% of the existing TCR Vβ genes and 2) the authors report that the PCR results are 
difficult to quantify or distinguish between irrelevant and phenotypically relevant TCRs.(55)  These 
limitations generate the potential for future and more advanced studies to investigate further 
into the clonality of muscle infiltrating T cells.  







Figure 3: Schematic of muscle section typically seen in inclusion body myositis patients. (A) 
Interstitial T cells invade endomysium regions of muscle. These T cells are typically polyclonal 
(red, orange, green, yellow dots). Autoinvasive T cells are found invading individual muscle 
fascicles and are clonal or oligoclonal (light blue dots). 
Other studies into the clonality of Vβ repertoire have yielded varying degrees of differences in 
the frequency of expression of the Vβ families both between studies and within individual 
patients.(56) Nonetheless, some similarities within the Vβ families have been identified, the most 
common of which include Vβ1, 2,5.1, 5.2, 6 and 8.(55, 56)  TCR sequencing of the CDR3 region 
shows that the clonality of these populations is identical between two commonly affected 
muscle groups in all patients (n=3).(56) Additionally, it has been shown that the T-cell clones 
predominate over time as was evident by TCR sequencing of muscle biopsies from two patients 
that had been taken nine years apart.(56) Both results indicate that T cells are responding to 
specific antigen(s) found within different muscle groups and that these antigens can 
continuously drive an immune response over time (e.g. years).  This is an important aspect in the 
context of understanding the pathophysiology of this disease; as continuous stimulation can lead 
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to T cell clonal exhaustion, functional decline in immune responses and increase susceptibility 
towards autoimmune diseases and cancer. (57) 
Both these studies are considerably outdated and contain significant limitations, most notably 
due to the techniques used for TCR sequencing. Current advancement in TCR sequencing such 
as Next Generation Sequencing (NGS) and cellular indexing of transcriptomes and epitopes by 
sequencing (CITE-seq), presents an opportunity to re-evaluate the clonality of T cell populations 
in IBM patients and is one of the aims of this study.    
1.5 Expansion of Rare T cells:  
We now turn our attention to two populations of T cells that have been demonstrated in 
previous studies to be increasing in IBM patients. Whilst these two populations don’t make up 
the majority of muscle infiltrating T cells, and are therefore deemed ‘rare,’ their prevalence 
within this disease indicates that they are nonetheless relevant and require better 
characterization. A heightened objective of this study is to affirm what veracities surrounding 
the immunobiology of these cells can be uncovered that may strengthen our understanding of 
these rare cells and how they relate to the pathology of inclusion body myositis.   
1.5.1 The Role of γδ T Cells  
Gamma delta T cells (γδ) are unconventional T-lymphocytes comprising of approximately 0.5-5% 
of the CD3+ population,(58-60) and possess features of both innate and adaptive immunity; with 
prominent anti-viral and anti-tumor abilities.(59, 61) These cells are typically found within epithelial 
tissues and lymphoid organs and are capable of responding to various pathogens.(60) Unlike the 
αβ T cell receptors (αβTCR), the γδ T cell receptor (γδTCR) is capable of recognizing antigens or 
tissue damage and induce cytotoxic effects, in an atypical, antigen and MHC independent 
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manner.(62, 63) Earlier studies have identified γδ T cells infiltrating the endomysial sites of muscle 
in inflammatory myopathies, such as polymyositis and IBM.(64) How γδ T cells function or what 
role they play in respects to IBM is under characterised, though some studies suggest that these 
γδ T cells may be recruited to muscle cells following an initial inflammatory event or that they 
play a role in removing damages cells.(64, 65)  
Upon exposure to specific cytokine milieu γδ T Cells exhibit a high degree of plasticity which 
leads to polarization towards distinct functional subsets.(66)  For instance, exposure to 
interleukin-2 (IL-2) or IL-18 polarizes the γδ T Cells towards a Th1-like phenotype with the 
potential for IFN-γ secretion.(66) Other phenotypes have that have been described for γδ T Cells  
include a Th2-like , Th17-like, follicular helper T cells (Tfh) or Treg cells. (66, 67)  In comparison to 
αβ T cells, γδ T Cells  possess adaptive characteristics including memory features after specific 
antigenic stimulation, and subsequently mount accelerated responses upon secondary 
challenge.(66) Memory subsets are identified by the expression pattern of CD45RA and CD27; 
though expression level of the lymphoid homing receptor CCR7 has also been utilized for 
deciphering γδ T Cells  memory subsets.(68) Naïve (CD45RA+, CCR7+ CD27+) and Central memory 
(CD45RA- CCR7+ CD27+), cells have no effector functions though the latter exhibits high 
proliferative potential.(66) Conversely,  effector memory (CD45RA- CCR7- CD27-) and terminally 
differentiated cells  (CD45RA+ CCR7- CD27-) are highly cytotoxic, produce vast quantities of 
effector cytokines, yet are limited in their proliferative capacity. (66) 
 
1.5.2 Vδ2+ and Vδ2- γδ T Cells lineages 
The γδ TCR variable gene (V) repertoire is relatively small in comparison to the αβ TCR repertoire, 
with only 9Vγ and 6Vδ gene segments identified.(60, 69) As such, these γδ T cells are delineated 
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into two main subsets that are based on the δ-chain variable region 2 and as such referred to as 
either Vδ2+ or Vδ2-. Both subsets have prominent effects on pathogen and tumour immunity. (59)  
The Vδ2+ subset makes up the majority of circulating γδ T cells and is frequently  co-expressed 
with Vγ9+.(59, 63) Interestingly, the Vδ2+ compartment can be further delineated into an innate- 
like Vγ9+ Vδ2+ subset and an adaptive Vγ9- Vδ2+.(59) The aforementioned Vγ9+ Vδ2+ subset 
primarily responds to phosphoantigens (P-Ags), produced by microbes and parasites or can 
respond to isopentenyl pyrophosphate (IPP), a metabolite that is found to accumulate in tumour 
cells.(59, 67) Alternatively, the Vγ9-Vδ2+ subset possess a more adaptive characteristic including 
clonal expansion and differentiation into effector cells in response to viral challenge.(59)  
The Vδ2- subset is predominated by the Vδ1+ cells that generally resides in epithelial tissues, 
dermis, spleen and liver, other members of the Vδ2- population include Vδ3 and Vδ5 but are far 
less common. (59, 68, 70, 71) The Vδ1 subset has important implications in the response against viral 
challenge, most notably against cytomegalovirus (CMV).(62) Studies involving transplant 
recipients, receiving organs from CMV infected donors were among the first to investigate γδ T 
cells immunity against CMV antigens.(68) These transplant recipients showed considerable lower 
numbers of Vγ9+Vδ2+ whilst the Vδ2- subset predominated.(68)  
 Cytomegalovirus is a β-herpesvirus and is a highly prevalent pathogen that infects between 30 
to 90% of the human population, yet it is typically asymptomatic unless the patient is 
immunocompromised.(68) Similar to many other herpesviruses, the cytomegalovirus is capable 
of remaining dormant within the host.(68, 71) Long-term CMV persistence has profound effect on 
immune function and recently, there has been much interest into the association between 
cytomegalovirus and autoimmune diseases such as rheumatoid arthritis and multiple 
sclerosis.(72) It has been hypothesized that the mechanisms by which autoimmune responses 
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arise as a result of CMV infection may be due to continual cycling between productive and latent 
forms of the virus resulting in a loss of self-tolerance to host proteins, and consequently 
progression towards autoreactivity.(73)   
1.5.3 Effects of Ageing and CMV on the γδ T cells  
Ageing is the major influencer for the decline in functionality within the immune system.(74, 75) 
During the ageing process, naïve T cells are gradually replaced by effector-memory (TEM) and T-
cell effector-memory re-expressing CD45RA (TEMRA) with a characteristic phenotype of late-stage 
differentiation (CCR7-, CD45RA+ CD27- CD28- CD57+).(57, 76)  Accumulation of highly 
differentiated cells overcrowds the T cell pool and leads to a decline in T cells specificity towards 
new antigens.(57) This shift in T cell compartment from naïve to TEM/ TEMRA cells contributes to 
reduced immune vigilance and progressive immune dysfunction.(57) This phenomenon is referred 
to as immunosenescence and is the likely contributor of increased susceptibility towards 
infections as well as the promotion of cancer and autoimmune diseases.(57, 74) Much of the 
research into the effects of ageing on immune system functions have focused on the αβ 
compartments. Changes in the γδ T cell population have only been marginally documented 
though the absolute number and percentages has previously been shown to decline in elderly 
populations.(77) Likewise, persistent herpesvirus  infections such as Epstein-Barr virus (EBV), 
herpes simplex virus or cytomegalovirus (CMV) have been recognized to promote the 
development of  immunosenescence by exhausting the naive T cell pool and promoting terminal 
differentiation of effector cells in both αβ and γδ T cells.(57, 71, 75) In healthy elderly populations 
there is a natural reduction in the Vδ2-,(71)  however CMV seropositivity is shown to accentuate 
the Vδ2- subsets. Additionally, the Vδ2- subset in elderly CMV positive individuals possesses a 
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highly differentiated status evident by CD45RA+, CD27,-CD28- and CD57+ whereas the Vδ2+ subset 
retains a less differentiated status in comparison.(58)  
The progression of IBM symptoms increases with age, meaning that immunosenescence will 
likely be a contributor of this disease etiology. Immunosenescence may also enable 
opportunistic viruses such as CMV to reactivate from their dormant state and contribute to 
worsened disease outcomes amongst the elderly. Our study will therefore investigate if γδ T cells 
are increased in IBM patients and determine the dominant γδ T cell subset.  
 
1.6 Expansion of T cell Large Granular Lymphocytes 
T cell Large granular lymphocytes (T-LGLs) are a well-defined altered population of T cells 
comprising about 10-15% of normal peripheral blood lymphocytes.(78) These cells are large (15-
18μm) and contain azurophilic granules.(79-81) Excessive proliferation of these T-LGL populations 
can result in a form of leukaemia, known as T cell large granular lymphocytic leukaemia.  T-LGL 
leukaemia is classified into two distinct entities: a  CD3+CD8+ predominantly TCRαβ or CD3-CD16+ 
CD56+ natural Killer (NK) lineage, the former of which is known to be associated with certain 
autoimmune diseases including rheumatoid arthritis.(79, 81)  
1.6.1 How T-LGL Arises 
This type of leukemia typically affects populations over the age of 60 and results in complications 
such as thrombocytopenia and neutropenia.(82) The pathoetiology of T-LGL leukaemia is 
hypothesized that chronic antigenic stimulation initiates the clonal expansion of cells with 
defective activation-induced cell death (AICD) pathways resulting in a neoplastic condition.(81)  A 
dominant feature of T-LGL is the ability of these cells to activate survival mechanisms that are 
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mediated by either loss or gain-of-function mutations, thereby enabling the dysregulated cell to 
continue proliferating.(83) One such gain-of-function mutation involves the signal transducer and 
activator of transcription 3 (STAT3) gene that has major implications in various human cancers, 
including T-LGL.(81, 83) Constitutive activation of STAT3 has been reported to increase the 
transcription of cell survival processes including the Janus Kinase (JAK) signaling pathway (Figure: 
3).(84) This JAK/STAT pathway is involved in cell differentiation, growth, migration, and 
apoptosis.(84) Conversely, dysregulation in this pathway has been linked to the development of 
leukemias.(84) in accordance with this, studies involving STAT3 mutations and T-LGL phenotype 
revealed that patients with a phenotype corresponding to CD8+, CD16+, CD56- showed an 
increase in STAT3 mutations.(85) Other molecular abnormalities in T-LGL leukaemia involves the 
resistance towards FAS/Fas-L mediated apoptosis.(81) FAS is a membrane receptor protein with 
a primary role in activating apoptosis (cell death).(81)  In T-LGL leukaemia, and other forms of 
leukaemia, a soluble FAS receptor (sFAS) acts as a decoy receptor for the FAS- ligand, thereby 
preventing apoptosis(79, 81) (Figure: 3). Proinflammatory cytokines such as interleukin-15 (IL-15) 
and growth factors  such as platelet-derived growth factor (PDGF) are implicated to play critical 














Figure 4: Development of TLGL leukemia: (1) Chronic antigen stimulation via pathogens or 
proteins induce an immune response (T cells). (2-3) These cells expand and can become mutated. 
(4) Mutated clones with specific survival mechanisms will proliferate, resulting in leukaemia. 
These TLGLs have several molecular abnormalities that enable them to avoid normal activation-
induced cell death pathways. (5) Soluble FAS acts as a decoy, thereby inhibiting apoptosis. IL-15, 
PDGF, and STAT3 mutations contribute to increased survival mechanisms. Adapted from 
Moignet, A and Lamy, T. 2018 (79)  
1.6.2 Diagnosis of T-LGL Leukaemia   
Diagnostic confirmation of T-LGL leukaemia is made based on histological and phenotypic 
features amidst an appropriate clinical context. Morphologically, these cells are large (15-18μm) 
with azurophilic granules and a round nucleus.(81) Clinically T-LGL leukaemia has a high 
prevalence amongst patients with autoimmune diseases.(81) Symptomatically these patients may 
present with persistent or recurrent infections, high occurrence of cytopenias (neutropenia, 
anemia, thrombocytopenia) and splenomegaly.(80, 81)  The normal number of T-LGLs that exist 
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within peripheral blood is expected to be around 0.25x109/, T-LGLs over 2x109/L is considered as 
expansile however a lower number (0.4x109/L) may be compatible with a diagnosis if clinical 
considerations are met.(80) Furthermore, phenotypic features including the upregulation of CD8+ 
CD57+ greater than 15% of the total T cell population, may also be considered as part of the 
diagnostic criterion.(78)  
1.6.3 Phenotype of T cell large granular lymphocytes  
Immunophenotyping of T-LGLs indicates these cells are a constitutively activated population of 
T lymphocytes demonstrated by the presence of CD3+, CD8+, TCRαβ+, CD57+, CD5-, CD94+, 
CD45RA+. (80, 81) The majority of these T-LGLs are CD8+, however, rare variants, including CD4+ and 
TCRγδ also exist.(81) Co-expression of CD8+ cells with the cell surface marker CD57+ is of particular 
interest and represents cells that are terminally differentiated as a result of chronic immune 
stimulation.(4) Other identifying characteristics include an increase in the expression of CD16+ 
and CD94+ and a decrease in CD5 expression.(78)  Similarly, the downregulation of CD5 is another 
significant feature of T-LGL leukaemia. Studies using CD5 knockout mice have suggested that 
CD5 functions to negatively regulate antigen-TCR signaling.(86) Therefore, hyperresponsive T cells 
are avoided as CD5 increases the threshold needed for the TCR-antigen activation.(86) 
Furthermore, CD5 plays a role in the regulation of antitumor responses and activation-induced 
cell death (AICD).(86) CD5 is consequently an important regulator of T cell homeostasis and 
maintenance of immune tolerance. Both CD5 and CD57 are used to distinguish T-LGLs and 
represent cells that are late differentiated yet hyperresponsive to antigenic stimulation. Two 
additional markers KLRG1 and Ki67, are useful for distinguishing the degree of differentiation 
and proliferation respectively and have been underreported within the context of T-LGL 
expansions, which presents an opportunity to analyze these markers and how they fit into the 
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T-LGL phenotype. On another note, many of these cell surface markers have previously been 
shown to increase during ageing. (76, 87) This calls into question, how specific are these markers 
for T-LGL detection and represents an area of uncertainty within the current literature.  
1.6.4 Associations Between T Cell Large Granular Lymphocytic Leukemia and IBM 
Recently, T-LGL leukaemia was shown to be associated with an American cohort of IBM patients 
(78) in addition to other autoimmune disorders, in particular Rheumatoid arthritis.(81, 82, 88) 
Greenberg and associates (2016)(78) successfully identified 22/38 (58%) of patients with inclusion 
body myositis that also met the diagnostic criteria for T-LGL leukaemia, compared to 14% of 
patients with other inflammatory myopathies (dermatomyositis, polymyositis, and necrotizing 
myopathy) and 0% of age-matched controls. Additionally, the authors found that IBM patients 
positive for T-LGL leukaemia had clinically significant decreases in muscle strength, compared to 
the IBM patients negative for T-LGL leukaemia. The authors, therefore, concluded that T-LGL 
might be contributing to an increase in the severity of the disease. It has been suggested that 
continual cytotoxic T cell stimulation to the antigen(s) (still unknown) in IBM patients may be 
responsible for the proliferation of CD8+ populations and that subsequent clones can become 
dysregulated and eventually neoplastic.(78, 80, 81)   
Given the evidence for how T-LGL leukaemia impacts the severity of IBM symptoms, particularly 
muscle weakness, we can appreciate how T-LGL leukaemia presents as an additional burden. 
Therefore, the objective of this study is to determine if our cohort of IBM patients is associated 
with T-LGL leukaemia and establish if the phenotype that characterizes T-LGL leukaemia is 
distinguishable using flow cytometry.  
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1.7 Conclusion and Research Benefit 
Inclusion body myositis is an inflammatory muscle disease that is difficult to diagnose given the 
symptoms are non-specific. It is also non-responsive to classical immunosuppressive therapies 
meaning that treatment options are limited. This study presents an opportunity to investigate 
the composition and phenotypes of these rare T cells in IBM patients and age-matched healthy 
donors that may provide previously unknown characteristics of these T cell populations. The 
increasing presence of these rare cells (T-LGL and gamma-delta T cells) in IBM suggests that they 
play an important role in the initiation or progression of the disease. The objective of this study 
is to enhance our knowledge of the characteristics and functionality of T-LGL and γδ T cells in 
patients suffering from IBM as well as in a healthy aged population.  This study will also 
investigate the T cell receptor (TCR) repertoire and determine the clonality of the peripheral 
blood T cells against muscle infiltrating T Cells. Accumulation of cells that express an identical 
TCR indicates that clonal expansion has occurred in response to antigenic stimulation.  
1.7.1 Hypothesis  
It is, therefore, hypothesized that: 1) phenotypic changes are observed in rare T cell populations 
in IBM patients but not in healthy donors; 2)  in IBM patients the TCR repertoire of peripheral 
and muscle T cells is restricted (clonal) indicating a common antigen as a target.  
 1.8 Research Aims: 
• Verify the association between T-LGL leukaemia and IBM and establish if the phenotype 
that characterizes T-LGL leukaemia is distinguishable using flow cytometry. 
• Confirm whether γδ T cells are more abundant in IBM patients compared to healthy 
controls. 
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• Compare the predominant subtype of γδ T cells between IBM patients and healthy 
donors to determine if alterations in the repertoire are evident.   
• Investigate whether these expanded populations express a restricted (clonal) TCR 
repertoire.  
To achieve this, peripheral blood and muscle samples were taken from IBM patients, and healthy 
donors will be analyzed to determine the phenotype of the rare T cell populations using flow 
cytometry. Additionally, Next Generation TCR sequencing will be utilized to identify the clonality 
of peripheral blood and muscle infiltrating T-cells. By examining the phenotypes and clonality of 
these cells, we can gain greater insights into the structures and functions of these populations 
that may uncover potential mechanisms for how IBM arises or progresses.  
1.9 Expected outcomes: 
1. If an association exists between IBM and T-LGL leukaemia we will observe a higher 
frequency of patients with expanded cells displaying a late-differentiated phenotype 
with altered expression of T cell markers that characterize T-LGL leukaemia.  
2. We expect IBM patients to have a higher proportion of CD3+ T cells with a γδ TCR, which 
mostly express the Vδ1 TCR and an effector memory re-expressing CD45RA (TEMRA) 
phenotype.  
3. It is expected that the clonal diversity of peripheral blood and muscle homogenate 
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Chapter 2: Materials and Methods  
2.1 Ethics approval and Patient Samples: 
The present study included 25 IBM patients (Male =10, Female=15, mean age=73) and 17 healthy 
controls (Male =10, Female=7, mean age=65). IBM patients were diagnosed based on histological 
studies and recruited via specialist appointment at the Institute for immunology and infectious 
disease (IIID), Murdoch University. Healthy controls were recruited via association with an IBM 
cohort patient (family member or spouse) or through external recruitment extensive exclusion 
criterion was set for healthy controls who had any known autoimmune diseases or immune-
related disorders and/or were using any immune-modulating medications/supplements. Some 
chronic conditions such as hypertension, high cholesterol were not excluded as these co-
morbidities have a high prevalence amongst this demographic of participants. Additionally, some 
H.C revealed previous cancer diagnosis; however those that were in remission or who were not 
receiving treatment for said cancer were accepted into the study. No exclusion criteria were set 
for IBM patients. Peripheral blood samples taken from IBM patients and healthy donors will be 
analysed using flow cytometry. Muscle biopsies may also be taken from IBM patients but are 
subject to availability. Blood and tissue samples were obtained in accordance with the Murdoch 
University Ethics Committee. ref 2015-111 and RAMP ref 0931_02_18.  All donors were informed 
and asked to provide written consent.  
2.2 Antibodies and Flow Cytometry  
Whole peripheral blood (approximately 30ml) was drawn from antecubital veins of IBM patients 
and healthy donors. Blood was collected by a research nurse and harboured in 3x heparinised 
tubes and 1x serum tube. Cells were stained with monoclonal antibodies conjugated to 
fluorochromes which were based on the following panels:  
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Panel 1: LGL-CD8 T cells: anti-CD4-FITC (BioLegend, clone OKT4), anti-CD94-PE (B.D Bioscience, 
clone HP-3D9), anti-CD56-PE-CF594 (B.D Bioscience,  clone B159), anti-TCRαβ-PE-Cy7 
(BioLegend, clone IP26), anti-CD16-AF647 (BioLegend, clone 3G8),  anti-KLRG1-APC (Invitrogen 
clone 13F12F2), anti-CD5-APC-R700 (B.D Bioscience, clone UCHT2), anti-CD8-APC-H7 (B.D 
Bioscience, clone SK1), anti-CD57-BV421 (B.D Bioscience, clone NK-1), anti-CD3-BV510 (B.D 
Bioscience, clone UCHT1). Panel 2 gamma-delta T cells #1: anti-TCRVδ1-FITC (Miltenyi Biotec 
clone REA173), anti-TCRVδ2-PE  ( BioLegend, clone B6), anti-TCRVγ9-PE-Cy5 (Beckman Coulter, 
clone IMMU360),  anti-CX3CR1-PE-Cy7 ( BioLegend, clone 2A9-1), anti-TCRγδ-APC-Vio770 
(Miltenyi Biotec, Clone RGA 591), CD57-BV421 (BD bioscience, clone NK-1), CD3-BV510 (BD 
bioscience, clone UCHT1). Panel 3 gamma-delta T cells #2: anti-TCRVδ1-FITC (Miltenyi Biotec 
clone REA173), anti-CCR7-PE (B.D Bioscience, clone 3D12), anti-Ki67-PrCP5.5 (B.D Bioscience, 
clone B56), anti-CX3CR1-PE-Cy7 (BioLegend, clone 2A9-1), anti-CD45RA-APC (BioLegend, clone 
HI100), anti-TCRγδ-APC-Vio770 (Miltenyi Biotec, clone RGA 591), anti-CD27-BV421 (B.D 
Bioscience, clone M-T271), anti-CD3-BV510 (B.D Bioscience clone UCHT1). Twelve-parameter, 
ten-colour flow cytometry was performed using Beckman Coulter Gallios Flow cytometer, with 
488nm, 633nm, and 405nm lasers.  Each sample was run for a minimum of 9min with a minimum 
number of 100,000 cells collected. 
 
2.3 Immunophenotyping  
100μl of blood is put into a 96 well plate for each of the following panels: 1) T-LGL-CD8, 2) 
gamma-delta T cell #1, 3) gamma-delta T cell #2. Anti-CCR7 was added to panel 3 only and left 
to incubate for 30min at room temperature. 50μl of antibody mix was added to their 
corresponding panels (panel 1,2,3). After incubation of 30 min, 2ml of BD lysing solution (stock 
solution @1/10 in H20) was added for red blood cell lysis. Once lysis was complete, samples were 
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washed twice with 2ml PBS, before cells were resuspended in 400μl of PBS 2% Fetal calf serum 
FC (Invitrogen). 50μl of Beckman Coulter Count beads (1000/μl) were added ready to run on the 
flow cytometer. To access intracellular molecules, peripheral whole blood was first stained using 
surface antibodies then fixed and permeabilised using fixation/permeabilization buffer kit (B.D 
pharmingen) Transcription factor fix perm (X4 solution) and Transcription factor buffer (X5 
solution) and further stained using anti-Ki67-PrCP 5.5 (B.D Bioscience, clone B56). The remaining 
blood samples were taken for biobanking, where 11ml of blood was added to 22ml of PBS. Next, 
the blood + PBS was carefully overlaid onto 16.5ml of ficoll then centrifuges at 800g for 15min 
at room temperature (RT) which creates a gradient to separate PBMCs. PBMCs were collected 
then washed twice with 50ml of PBS and centrifuged at 400g for 10min, RT between washes.  
Cells were resuspended in 10ml PBS and the viability was assessed. Cells were diluted at 
10e7/800μl in 10% dimethyl sulfate and 90% fetal calf serum, FC (Invitrogen).  Finally, Serum was 
collected and centrifuged at 4000g for 10min, RT and then aliquoted into 1.5ml Eppendorf tubes. 
PBCMs and Serum were stored under cryopreservation conditions located at the IIID.  
 
2.4 CD4/CD8 Separation  
Cryopreserved PBMCs were thaw in 37OC water bath. Next, cells were placed in culture medium 
with 10% fetal calf serum (FCS) and 20 ng/ml rhIL-2 until the following day. 
1st step: T cell isolation with StemCell Technologies EasySep T cell isolation kit (negative 
selection). cells were resuspended at 50.10e6/ml in PBS, 2% FCS, 1 mM EDTA (no less than 
0.25ml) in 5ml PS tube, before 50µl of isolation cocktail (12.5ul / 250ul sample) was added and 
incubated for 5 min at room temperature (RT). 40ul/ml of rapidspheres were added to samples 
(> 10ul / 250ul sample) and topped up to 2.5ml of PBS/FCS/EDTA buffer. Tubes were placed on 
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StemCell Technologies EasySep magnet and left for up to 3min at room temperature. Negatively 
selected T cells were collected in supernatant.  
2nd step: CD4 / CD8 separation with StemCell Technologies EasySep CD4 positive selection / 
bead release kit. Lymphocytes were resuspend at 100.10e6/ml in PBS, 2% FCS, 1 mM EDTA (no 
less than 0.25ml) in 5ml polystyrene tube with 100ul CD4 positive selection cocktail added (> 
25μl for 250μl) and left to incubate for three min RT. 100ul/ml rapidspheres were added to mix 
(> 25μl for 250μl), left to incubate for a further 3 min RT, then topped up with 2.5ml 
PBS/FCS/EDTA buffer. Tubes were placed on StemCell Technologies EasySep magnet and left for 
5min at RT. Negative fraction (CD8+) cells were collected in supernatant. Lymphocytes were 
washed in 2.5ml PBS/FCS/EDTA buffer and once again placed on CD4 positive selection magnet 
for another 3min at RT. CD4+ cells attached to positive selection beads were released using 100μl 
release buffer (> 25μl for 250μl). Tubes were topped up to 2.5 ml with PBS/FCS/EDTA buffer and 
once again placed on a magnet for 5min at RT. Collected CD4+ and CD8+ cells were added to 1ml 
lysis buffer (Triton X 100, RNAase OUT, 10nM dNTPs, water). Ready for TCR sequencing. A small 
aliquot of isolated T-cells was used for purity check by flow cytometry, using anti- CD3 BV510, 
anti-CD4 FITC and anti-CD8 APC-H7. 
T cell isolation from cryopreserved muscle biopsy:  muscle biopsies were thawed and cut into 
7micron thick sections. 70 sections were pooled corresponding to 0.5mm thickness were 
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2.5 TCR Bulk Sequencing:  
CD4/CD8 from PBMCs and muscle biopsy samples were analysed by high-throughput deep TCR 
sequencing and performed by IIID core sequencing services. RNA was extracted from all samples 
using lysis buffer (Triton X 100, RNAase OUT, 10nM dNTPs, water), then reversed transcribed 
into cDNA using a thermocycler. After cDNA conversion, 30µl of 10nM Tris was added to 20µl 
cDNA and purified using Ampur beads. The sample was then diluted in 25ul of 10nM Tris before 
23uL was transferred straight into KAPPA HiFi 1st RD PCR run for 25 cycles. 5µl of PCR products 
were run on 1% agarose gel electrophoresis for visualisation before quantification using 
nanodrop. Purified products were pooled and based ID before library preparation. TCR 
sequencing was performed using a MiSeq (Illumina) Next Generation Sequencer (NGS).  
2.6 TCR repertoire data analysis  
V, D, and J genes and CDR3Vβ amino acid sequences were identified and mapped using circos 
spots generated via in-house computing software iiidVGAS. Circos spots show each unique CDR3 
amino acid sequence as a coloured box; the size of each box represents each CDR3 frequency 
within the repertoire. Only the most prevalent CDR3 sequences were analysed from each donor 
list. Circos spots for TCRVβ and TCRβJ arrangements were analysed from donors CD4, CD8 and 
muscle samples. A ribbon/band is used to show corresponding TCRVβ and TCRβJ paired 
arrangements. Colour and ribbon width determine the frequency of the indicated rearranged V, 
D, J genes.  
2.7 Statistical Methods 
Flow cytometry analysis of lymphocytic populations is achieved using FlowjoTM 10.5.3 for 
Windows (Flowjo TM software Inc. USA). Statistical analysis was performed using GraphPad 
PRISMTM 8.0 for Windows (GraphPad Software Inc., San Diego, USA).  Each data set was assessed 
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for normality using the Shapiro-Wilk normality test. A two-tailed student’s t-test will be used to 
assess the mean ± SEM for normally distributed data and a Mann-Whitney U test will be used to 
assess non-parametric data. Wilcoxon matched-pairs sign rank test is used for the paired non-
parametric test or a paired T-test is used for parametric data.  One-way analysis of variance 
(ANOVA) is used for grouped analysis with post-hoc test (Dunn’s or Bonferroni) indicated where 
appropriate. A correlation analysis was assessed for non-parametric data by Spearman’s 
correlation. A p-value of < .05 will be considered statistically significant. 
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Chapter 3: Results 
3.1 Demographics:  
Table 2 summarises the demographical data from the IBM and healthy control cohorts that were 
included in this study. Together there were 25 IBM (F= 15, M= 10, mean age=73) and 17 healthy 
donors (F=7, M=10, mean age=65). CD4/CD8 ratios, the percentage of lymphocytes that are T-
LGLs and the number of T-LGL/L blood are provided for each donor (IBM and H.C). Table 2 also 
shows the T-LGL status for each donor with a “+ symbol” indicating T-LGL positive status, a “– 
symbol” indicates T-LGL negative status and “expansile” indicating a high T-LGL count but no 
other diagnostic parameters are met.  The percentage of γδ T cells in the total CD3+ population 
are also provided for each patient.  
The majority of our IBM and healthy donors were co-habitants (spouse or family member), which 
reduces biases surrounding environmental impacts on immune changes. Our cohort 
demographic centers around an ageing population in which the prevalence of co-morbidities is 
highest. Table 3 demonstrates the number of healthy donors for each co-morbidity that were 
accepted into this study. We provided each healthy control with a thorough questionnaire 
regarding medical history and medication usage and excluded participants with any known 
diseases or medications that would directly impact immune function. No exclusion criteria were 
set for IBM patients and as such, we did not record co-morbidities or medication usage for these 
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Table 2: Summarized clinical information of all IBM and Healthy control included in the study 
 Age Sex Condition CD4/CD8 
ratio 
Frequency of T-LGLs in 
CD3+ TCRαβ (%) 
Number of LGL 
per 1L blood 
T-LGL status  % γδ T 
cells  
1 58 F IBM 0.3 39% 4 X109 + 5.67 
2 77 F IBM 3.7 4.4% 7.2x108 - 0.31 
3 88 M IBM 2.9 7% 4.5x108 - 0.29 
4 74 F IBM 2.67 5.2% 3.3 x108 - 4.4 
5 76 F IBM 1.63 1.5% 2.65x108 - 4.71 
6 78 M IBM 1.9 5.3% 4.3 x108 - n/a 
7 81 F IBM 0.5 37% 6.8x109 + n/a 
8 62 F IBM 2.23 4.9% 1.87x109 Expansile  n/a 
9 81 M IBM 2.2 0.08% 4.2 x106 - n/a 
10 75 F IBM 1.1 7.8% 2.91x108 - n/a 
11 62 M IBM 8.4 0.09% 3.72 x106 - n/a 
12 69 F IBM 2.9 0.01% 1.57x108 - 2.26 
13 86 F IBM 0.8 0.15% 1.9x109 + 1.41 
14 73 F IBM 1.1 2.8% 1.6x109 + 0.77 
15 78 F IBM 1.6 10% 1.12x109 + 0.54 
16 63 F IBM 2.2 12% 1.21x109 + 1.02 
17 80 M IBM  2.7 0.2% Nil - 1.65 
18 76 M IBM 2 3.2% 9.61x108 - 1.57 
19 83 F IBM 2.2 2.2% 9.8x107 - 0.37 
20 61 M IBM 9.7 1.3% 2.9x107 - 0.8 
21 81 M IBM 5.5 4.6% 4.8x106 - 1.53 
22 72 F IBM 2 0.9% 4.9x107 - 0.37 
23 74 M IBM 1.7 6.18% 1.03x109 Expansile  1.35 
24 71 F IBM 1.9 20% 3.8x109 + 1.14 
25 67 M IBM 1.7 8.2% 5.7x109 +  5.55 
26 59 F H.C 3.2 5.1% 1.10 X109 Expansile n/a 
27 65 M H.C 2.1 8.11% 1.68x109 Expansile  2.66 
28 55 M H.C 2.3 3.7% 4.0x106 - 5.32 
29 52 F H.C 4.3 0.9% 1.02x106 - 0.52 
30 69 M H.C 4.5 0.69% 9.27x106 - 0.99 
31 78 F H.C 2.9 0.8% 3.5x107 - 2.8 
32 72 M H.C 4.3 1.04% 7.7x107 - 1.11 
33 75 F H.C 1.39 71.% 2.31x108 - 1.61 
34 72 F H.C 1.3 10.8% 2.9x109 + 3.21 
35 78 M H.C 2.5 4.17% 2.52x108 - 5.14 
36 73 M H.C 1.7 9.4% 2.3x109 +  2.59 
37 68 M H.C 2.5 2.89% 7.6x108 - 2.71 
38 55 F H.C                 4.5 0.5% 4.9x107 - 1.36 
39 62 M H.C                 2.4 0.06% 9.8x106 - 1.6 
40 76 M H.C                 2.5 2.1% 4.25x108 - 1.04 
41 47 M H.C                 1.5 9.8% 1.2x109 + 3.34 
42 49 F H.C                 3.5 0.9% 1.7x107 - 1.37 
Abbreviations: IBM=Inclusion Body Myositis. F= Female. M=Male. n.a= not available. Nil- no 
detectible count   
 
Page | 48  
 
 
Table 3. The number of healthy controls with co-morbidities and medication use.  
 
Co-morbidities Number of Healthy Controls 
Hypertension 5/17 
ACE Inhibitors  2/17 
Beta- blockers  3/17 
Ca2+ blockers 1/17 
Aspirin  2/17 
Angiotensin-2 antagonist 1/17 
High Cholesterol 5/17 
Statins 5/17 
Cancer  6/17 
Leiomyosarcoma 1/17 
Benign prostate hyperplasia  2/17 
Prostate Cancer- remission 2/17 
Melanoma 1/17 
Influenza (within 6 weeks) 1/17 
Flu Vaccination (<3 weeks) 1/17 
Migraines 3/17 
Serotonin agonist  1/17 
Anti-GCRP antibodies 1/17 





Thalassemia  1/17 
Haemochromatosis 1/17 
Epilepsy  1/17 

































Figure 5: Flow cytometry analysis for detection of T-LGL leukaemia between IBM patients and 
Healthy Controls. A) fresh whole blood was stained with antibodies using the methods described 
above. The data was analysed by gating the lymphocyte population (1), singlets (2) CD3+, TCRαβ+ 
(3) expression of CD4+ and CD8+ (4) expression of CD5+ and CD57+ (5) (flow analysis taken from 
donor 7). B) stages of differentiation based on CD8+ with a gain of CD57 and the downregulation 
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Figure 6: Frequencies and ratio of CD4, CD8, and frequency of T-LGLs in T cell population. A-C) 
Frequency of CD4, CD8 and CD4/CD8 ratio is shown between IBM patients (green symbols, n=25) 
and H.C (blue symbols n=17). Frequency statistics were acquired using unpaired student t-test; 
Error bars indicate mean ± SE. (D) Frequency of T-LGLs (gated on CD8+ CD57+) in total CD3+ TCRαβ 
population is shown between IBM (green symbols n=25) and H.C (blue symbols, n=17). The 
dotted line indicates the highest percentage that is considered the normal number of CD8+ CD57+ 
cells in the T cell population. Frequency statistics were acquired using the Man-Whitney U test 
for non-parametric data (P-value = 0.491). Error bars indicate median ± interquartile ranges. * 
P-value <0.05, **P-value <0.005, ***P-value <0.001 #P-value= not significant 
3.2  Detection of T-LGL Expansions in IBM patients vs. Healthy Controls.  
T-LGL expansions in IBM patients and healthy donors were detected by flow cytometry. The 
typical gating strategy used for T-LGL detection is given in figure 5A. Lymphocytes were gated 
based on FSC/SSC profile and exclusion of doublet/dead cells, then gating on CD3+ TCRαβ and 
then gating on CD8+. Here we have used the surface markers CD5- and CD57+ gated on CD8+ to 
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upregulation and CD5 downregulation (gated on CD8+) between an IBM patient (CD5+ CD57-) 
taken from donor 9, IBM patient positive for CD5 and CD57 taken from donor 8, and an IBM 
patient, showing CD5- CD57+ taken from donor 7. The comparison shows the gain of CD57 
expression and the downregulation of CD5 which is most evident in the CD5-CD57+ population. 
Expansion of CD5-CD57+ cells > 0.4x109/1L blood was identified in 36% (9/25) IBM and 29% (5/17) 
Healthy donors. Method of calculation included the total number of CD5- CD57+ cells in CD8+ 
population then standardising against the number of Beckman Coulter count beads (1000 
cells/μl), this value was multiplied by the total volume of Count beads used then multiplied by 
1x106 to achieve total cells per 1L blood.  
Criteria for diagnosis of T-LGL leukaemia requires a multi-parameter analysis and includes the 
above criteria T-LGL expansion > 0.4x109/1L blood. Additionally, expansion of T-LGLs may be 
determined using the expression of CD8+ CD57+ which shows an increase of >15% of total CD3+ 
TCRαβ lymphocyte population. This expansion can be seen in 12% (3/25) IBM and 0% (0/17) HC 
(figure 6D). Finally, figure 6A-C shows the percentage of CD4+, CD8+ and the ratio of CD4 to CD8 
between IBM patients and healthy donors, with 5/25 (20%) IBM and 2/17 (11%) H.C having a 
reduced CD4 ratio of <1.5. This reduction in CD4/CD8 ratio is not due to any significant reduction 
in CD4 count (mean CD4/μl 618, n=25 IBM vs mean CD4/μl 804, n=17 H.C; P-value=0.1056) 
(supplementary figure 1 A). Though the CD8 counts were admittedly much lower in some IBM 
patients (donor 11, 20 and 21) and therefore may contribute to a greater CD4/CD8 ratio 
observed (supplementary figure 1 B). Additionally, no statistical difference is observed within 
frequency of CD4 or CD8 (P-value= 0.1663; P-value=0.1948 respectively) or the CD4/CD8 ratio 
between IBM patients and H.C (P-value= 0.1780).  
Page | 52  
 
Our analysis revealed a substantial level of variability amongst IBM patients and healthy donors 
for the above characteristics.  This has generated considerable ambiguity for diagnosing T-LGL 
leukaemia. For our purposes the parameters for T-LGL leukaemia detection in order of 
preference is (1) T-LGL count > 0.4x109/1L blood, (2) evident changes in phenotypic expression 
of CD57 upregulation CD5 downregulation (gated on CD8), expression of CD94 and CD56 may 
increase likelihood of T-LGL malignancy, though their upregulation is not a key determinant for 
this leukaemia. (3) ratio of CD4/CD8 ratio <1.5, (4) increase of CD57 on CD8 >15% of total CD3+ 
TCRαβ lymphocyte population. Based on this, our analysis successfully identified 35% of IBM 
patients and 17% of healthy donors that show a typical criterion for T-LGL leukaemia.  
  


























Figure 7: Expression of phenotypic changes in Large Granular Lymphocytes in IBM patients and 
Healthy Controls. A) Phenotypical characteristics for IBM patient positive for T-LGL leukaemia 
(donor 7) shows increased expression of CD57 on CD8+ cells, downregulation of CD5 and increase 
expression of CD94 and increased expression of CD56- B) Phenotypical characteristics for IBM 
patient negative for T-LGL leukaemia (donor 8)  showing expression of CD57, CD5, CD94 and 
CD56 gated on CD8+ Cells. C) Phenotypical characteristics for Healthy control (donor 31) showing 
expression of CD57, CD5, CD94 and CD56 gated on CD8+ Cells. D) Frequency of CD57 on CD8+ T 
A. IBM+ T-LGL 
 
B. IBM Patient  
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cells displayed as mean ± 𝑆𝐸  between IBM +T-LGL (green symbols n=8), IBM no T-LGL (red 
symbols n=17) and Healthy controls (blue symbols n=17). Frequency statistics were calculated 
using one-way ANOVA (P=<0.0001) and Bonferroni’s post-hoc test comparing IBM +T-LGL vs. 
IBM no T-LGL, IBM + T-LGL vs. healthy controls and IBM no T-LGL vs. healthy controls. E) 
Frequency of CD5- on CD8+ cells displayed as median ±  interquartile ranges between IBM +T-
LGL (green symbols n=8), IBM no T-LGL (red symbols n=17) and H.C (blue symbols n=17). 
Frequency statistics were analysed using Kruskal-Wallis (ANOVA) (P-value= 0.0008) and Dunn’s 
post-hoc comparison tests comparing IBM +T-LGL vs. IBM no T-LGL; IBM + T-LGL vs. healthy 
controls and IBM no T-LGL and healthy controls. * P-value <0.05, **P-value <0.005, ***P-value 
<0.001 #P-value= not significant 
Table 4: Averages and ranges of antibody with the frequency of donors  
Antibody Mean/ Range 
(%) 
Frequency of Donors (%) 
IBM +T-LGL IBM no T-LGL HC 
CD57+ 30.2 (0.13-60.4) 8 5 6 
CD5- 1.0 (0-6) 8 2 6 
CD94+ 8.21(0.064-80.7) 3 1 3 
CD56+ 2 (0-8.5) 2 0 0 
KLRG1+ 73 (32.6-100) 2 3 8 
 
3.3 Aberrant Expression of T-LGL surface markers.  
Immunophenotyping of T-LGL leukaemia not only helps with diagnostic confirmation but can 
lead to a greater understanding of the immunobiology of these cells and how they may impact 
the pathogenesis of IBM. Five key surface markers (CD57, CD5, CD94, CD56 and KLRG1) were 
examined using flow cytometry and demonstrated to be abnormally expressed. Figure 7A-C 
shows the comparison between the surface marker expression phenotypes that were observed 
between an IBM patient positive for T-LGL Leukaemia (figure 7A) an IBM patient without T-LGL 
leukaemia (figure 7B) and the phenotype of healthy control (figure 7C).  
Expression of these markers displays considerable individual heterogenicity amongst the subject 
groups; thus, determining what was considered as “increased expression” was inherently 
difficult and poorly described throughout the literature. As such, a quantitative assessment using 
the mean percentage of each antibody was used as the benchmark and expression levels above 
which would thereby be considered as “increased expression” (Table 4). All IBM T-LGL + patients 
Page | 55  
 
show a gain of CD57+ on CD8+ cells (>30% indicated by the dotted line in figure 7D), whereas only 
5/17 (29%) of IBM no T-LGL patients and 6/17 (35%) of H.C show increased expression. IBM T-
LGL + patients, exhibit an increase in CD5 is downregulation, (>1% as indicated in figure 7E). 
Additionally, the downregulation of CD5- on CD8+ cells (>1% indicated by dotted line figure 7E) 
is seen in 2/17 (11%) of IBM no T-LGL patients and 6/17 (35%) of healthy controls. The average 
frequency of CD94 expression was 8%. Using this as the benchmark for increased expression of 
this marker, the gain of CD94 was seen in 3/8 (37.5%) of IBM-T-LGL+ patients, compared to 1/17 
(5%) of IBM no T-LGL and 2/17 (11%) of healthy controls (Table 4 and Supplementary Figure 1C-
D). Moreover, increased expression of CD56 is considered a poor prognostic factor for T-LGL 
leukaemia yet  expression of this marker greater than the average (2% Table 4 and 
supplementary figure1D) is only observed in 2/8 (25%) of IBM T-LGL+ patients. Meanwhile 0/17 
(0%) of IBM no T-LGL and 0/17 (0%) of H.C show a gain in CD56.  Lastly, the frequency of Killer 
cell lectin-like receptor G1 (KLRG1) was assessed; however, this marker was a late addition to 
our analysis (figure 10). As such, only 9 IBM patients (2 IBM + T-LGL and 7 IBM no T-LGL) and 15 
healthy controls were assessed for this marker. Nonetheless, our results have shown that 2/2 
(100%) of IBM T-LGL+ subjects show increase of KLRG1 above the average (73%) compared to 
3/7 (42%) of IBM no T-LGL and 8/15 (53%) of healthy controls showed increased frequency of 
KLRG1 above 73% (Table 4 and figure 9E-F).  
The frequency of CD57+ on CD8+ cells is given in figure 7D where the results from  one-way 
ANOVA  indicate a significant difference (P-value= <0.0001) whereas multiple comparison 
analysis shows the difference between T-LGL+ patient  IBM T-LGL- (mean 49.06, vs n=8 mean 
19.88,n=17 respectively; P-value= <0.0001). The difference between T-LGL+ patient and healthy 
controls (mean 49.06, n=8 vs mean 21.58, n=17, respectively; P-value= 0.0001). Lastly the 
difference between IBM T-LGL- and healthy control (mean 19.88, n=17 vs mean 21.58, n=17 
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respectively; P-value= >0.9999).Figure 7E shows the frequency of CD5- on CD8+ cells between 
IBM + T-LGL+ patient, IBM T-LGL- patient and H.C. The results from Kruskal-Wallis (ANOVA) (P-
value= 0.0008), whereas Dunn’s post-hoc comparison tests reveals the difference between T-
LGL+ patient  IBM T-LGL- (mean rank 35.19, n=8 vs mean rank 15.35,n=17 respectively; P-value= 
0.0005). The difference between T-LGL+ patient and healthy control (mean rank 35.19, n=8 vs 
mean rank 21.21, n=17, respectively; P-value= 0.4908). Lastly the difference between T-LGL- and 
healthy controls (mean rank 15.35, n=17 vs mean rank 21.21, n=17 respectively; P-value= 
0.0233). 
Changes in surface marker expression were observed in (32%) of IBM patients with T-LGL 
expansions and demonstrate a late-differentiated phenotype consistent with that observed 
throughout the literature (CD3+, TCRαβ +, CD8+, CD57+ CD5-, CD94+ and CD56-). However, our 
analysis has shown considerable individual variation in the frequency of aberrant cell surface 
markers amongst subject groups, with a significant proportion of healthy controls and IBM no T-





















Figure 8. Flow Cytometry analysis for the detection of T-LGL leukaemia is healthy controls. A) 
Fresh whole blood was stained with antibodies using the methods described above. The data 
was analysed by gating the lymphocyte population and exclusion of dead and doublet cells (not 
shown) CD3+, TCRαβ+ (1) expression of CD4+ and CD8+ (2) expression of CD5+ and CD57+ (3) (flow 
analysis taken from donor 34). B) Phenotypic expression showing an increase in CD57+, an 
increase in CD5-, an increase in CD94+, and an increase in CD56- gated on CD8+ T cells.   
 
3.4   Expansion of T-LGLs is Observed in Healthy Controls.   
Figure 8A-B shows the aberrant expression of cell surface markers phenotypical of T-LGL 
expansions in healthy control (donor 34). Figure 3A shows the typical gating strategy used for T-
LGL detection. Lymphocytes were gated based on FSC/SSC profile and exclusion of doublet/dead 
cells (not shown) then gating on CD3+ TCRαβ (1) then gating on CD8+ (2) and finally gating on 
CD5 CD57 (3). Again, we use the surface markers CD5- and CD57+ gated on CD8+ to identify our 
T-LGL population. This healthy control (donor 34) was a 72-year-old female with a CD5-CD57+ T-
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LGL count of 2.9x109/L, well within the category for T-LGL leukaemia (LGL count >0.4-2x109/L). 
Donor 34 also had a CD4/CD8 ratio <1.5 but the percentage of CD8+ CD57+ in total T cell 
population was less than 15% (9.3%). Donor 34 also shows the characteristic phenotype for T-
LGL expansions (CD3+, TCRαβ+, CD8+, CD57+, CD5-, CD56- and CD94+) as well as an increase in 
KLRG1 expression. These phenotypical characteristics are seen in one other healthy control  
(donor 41) while three healthy controls (donor 26, 27 and 36) show expansion of T-LGLs (>2x109) 
and some phenotypic characteristics yet do not display an inverted CD4/CD8 ratio or an increase 
in CD8+ CD57+ >15% total T cell population. Furthermore, one healthy control (donor 35) showed 
an altered phenotype of CD57+ CD5- above average (>30% and 1% respectively, Table 3) but did 
not show increased expansion of T-LGLs (> 0.4x109/L). Overall, these results show that 2/17 
healthy controls are consistent with the above 3/4 parameters (T-LGL count >0.4x109, 
phenotypic changes and a CD4/CD8 ratio <1.5) and 1/17 H.C showed 2/4 parameters (T-LGL 
count >0.4x109 and phenotypic changes).  Therefore, we can identify 3/17 of our healthy controls 
expressing characteristics that identify these donors as T-LGL leukaemia positive.   







Figure 9. Relationship between patient age/ duration of IBM symptoms and total T-LGL count 
in 1L blood. A) relationship between IBM patient age (years) and total T-LGL count in 1L blood. 
Statistical analysis conducted using Spearman’s correlation and is shown for IBM patients (n=25). 
B) Relationship between healthy control age (years) and total T-LGL count in 1L blood. Statistical 
analysis conducted using Spearman’s correlation and is shown for H.C (n=17). 
3.5 No association exists between age and T-LGL count.   
Figure 9A-B demonstrates the associations between donor age (years) and the total T-LGL count 
in 1L blood. Given that some of the phenotypic changes (i.e. CD57 upregulation) seen in T-LGL 
positive patients are associated with ageing, we hypothesize that advancing age would be a 
predictor of T-LGL leukaemia. In figure 9A, there was no significant correlation between IBM 
donor age (years) and T-LGL count (Spearman’s coefficient= 0.3725; P-value 0.0878). The 
youngest IBM T-LGL positive patient is 58 and the oldest is 86 with a mean age of the whole IBM 
+T-LGL population is 72. Figure 9B shows the association between healthy controls age (years) 
and total T-LGL count in 1L blood, which again shows no significant correlation (Spearman’s 
coefficient= 0.1598; P-value 0.6368). Both these results show no association between increasing 





























































Figure 10. Expression of KLRG1 on the four CD5 CD57 populations and CD8+T cells. A) Flow 
cytometry for CD5 CD57 populations was analysed by gating the lymphocyte population and 
exclusion of dead and doublet cells, CD3+, TCRαβ+, expression of CD4+ and CD8+ (not shown), CD5 
CD57 populations (flow analysis taken from donor 26). B) Frequency of KLRG1 on CD5+ CD57-. C) 
Frequency of KLRG1 on CD5- CD57+. D) Frequency of KLRG1 on CD5+ CD57+. B-D Statistics were 
acquired using Kruskal-Wallis (ANOVA) with Dunn’s post hoc test. Error bars indicate median 
± interquartile ranges between IBM T-LGL+ (n=2) IBM no T-LGL (n=8) H.C T-LGL+ (n=3) and H.C 
(n=12). E) Flow cytometry for KLRG1 expression was analysed by gating the lymphocyte 
population and exclusion of dead and doublet cells, CD3+, TCRαβ+, expression of CD4+ and CD8+ 
(not shown), expression of KLRG1 (flow analysis taken from donor 26). F)  Frequency of KLRG1 
(gated on CD8+ T cells). Statistics were acquired using one-way ANOVA with Bonferroni’s post 
hoc test. Error bars indicate median ± interquartile ranges between IBM T-LGL+ (n=2) IBM no T-
LGL (n=8) H.C T-LGL+ (n=3) and H.C (n=12). * P-value <0.05, **P-value <0.005, ***P-value <0.001 
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3.6 Killer cell lectin-like receptor G1 (KLRG1) frequency increases with CD8+ differentiation  
Killer cell lectin-like receptor G1 (KLRG1) is an inhibitory co-receptor that is expressed by 
activated T lymphocyte and natural killer cells.(89) The effects produced by this receptor mount 
interference with proliferation signaling and is deemed as an additional marker of late-stage 
differentiation.(89) Previous literature has not fully investigated this marker in the context of IBM 
and T-LGL leukaemia which presents us with the opportunity to do so. The frequency of KLRG1 
on the three CD5 CD57 populations amongst the various IBM and H.C groups is given in Figure 
10B. KLRG1 frequency is shown to increase as the stages of differentiation (gain of CD57) and is 
consistent across all IBM and H.C groups. For instance, in figure 10B (CD5+CD57- population) the 
frequency of KLRG1 in all donor groups sits around 70%, however in Figure 10C (CD5+CD57+ 
population) the frequency increases to 90-95% (seen in all donor groups). Similarly, figure 10D 
shows an increased frequency of KLRG1 (again around 95-100%) in the CD5-CD57+ population 
compared to the less differentiated CD5+CD57- population. However, in the late-stage 
differentiated population (CD5-CD57+) the H.C + T-LGL group showed a reduction in KLRG1 
frequency. No statistical significance was observed between any of the CD5CD57 population or 
donor groups. Moreover, Figure 10E-F shows the gating strategy and frequency for KLRG1 on 
CD8+ T cells (respectively). Here, the frequency of KLRG1 is slightly higher in IBM + T-LGL patients 
compared to the other donor groups; however no significant difference is observed (P-
value=0.6016). Overall, KLRG1 frequency is increased based on population differentiation status 
(e.g. gain of CD57+) and is shown to be slightly increased in T-LGL positive donor groups (IBM and 
H.C) however all results show no statistical significance is observed between IBM patients and 
H.C.   
 











Figure 11. Expression of Ki67 on the four CD5 CD57 populations A) Flow cytometry for CD5 CD57 
populations was analysed by gating the lymphocyte population and exclusion of dead and 
doublet cells, CD3+, TCRαβ+, expression of CD4+ and CD8+ (not shown), CD5 CD57 populations 
(flow analysis taken from donor 26). B) Frequency of Ki67 on CD5+ CD57-. C) Frequency of Ki67on 
CD5+ CD57+. D) Frequency of Ki67 on CD5- CD57+. B-D Statistics were acquired using one-way 
(ANOVA) with Bonferroni’s post hoc test. Error bars indicate mean ± SE between IBM T-LGL+ 
(n=7) IBM no T-LGL (n=11) H.C T-LGL+ (n=3) and H.C (n=14). * P-value <0.05, **P-value <0.005, 
***P-value <0.001 #P-value= not significant. 
 
3.7  Expression of Ki67 shows that Large granular lymphocytes are proliferating  
Another marker that has been poorly described in previous literature in the context of IBM and 
T-LGL leukaemia, is the proliferation-associated marker Ki67. Ki67 is a protein that is expressed 
during all stages of the cell cycle and mitosis, yet is not expressed during G0 phase.(90) Therefore 
it is useful for analyzing the proliferation potential of the populations at varying stages of 
differentiation. This is important as late-differentiated cells get have a reputation for being 
clonally exhausted/ senescent. Figure 11B displays the frequency of Ki67 within the CD5+CD57- 
population, in which no statistical significance can be found between donor groups (P-
value=0.1665). In CD5+CD57+ population (figure 11C) however, frequency of Ki67 is shown to be 
statistically significant (P-value= 0.0187) and is most noticeable between IBM + T-LGL and IBM 
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value=0.0068). A statistical difference is also seen between IBM + T-LGL and H.C no T-LGL (mean 
4.77 n=7 IBM + T-LGL vs mean 1.94 n=14 H.C no T-LGL; p-value=0.0454).  
The expression of Ki67 is greatest within IBM T-LGL+ populations across all CD5CD57 population 
in comparison to other donor groups. The final CD5-CD57+ population represents the most 
differentiated cells for which the frequency of ki67 is reduced in comparison to figure 11B-C. In 
Figure 11D, the IBM +T-LGL group shows the highest frequency of Ki67 in this late-differentiated 
population, indicating they are still capable of proliferation. However, statistically, there is no 
difference between the donor groups for this population (p-value 0.4925). The results presented 
herein figure 11 suggest that there is an increase in the frequency of Ki67 between CD5+CD57- 
and CD5+CD57+ populations whereas the Ki67 frequency decreases significantly in the late-
differentiated CD5-CD57+ population. However, in all three populations, the IBM + T-LGL groups 
show the highest frequency of Ki67 in comparison to other donor groups.  
  





















Figure 12. γδ T cell and corresponding subsets between IBM patients and Healthy controls. A) 
fresh whole blood was stained with antibodies using the methods described above. The data was 
analysed by gating the lymphocyte population (1), singlets (2) CD3+, TCRγδ+ (3) expression of 
Vδ1+ vs Vδ2+ (4) expression of Vδ2+ vs Vγ9+ (5) expression of Vδ1+ vs Vγ9+ (6) (flow analysis 
taken from donor 1).  B) percentages of γδ T cells between IBM (green symbols n=17) and H. C 
(blue symbols n=16) Error bars indicate median ± interquartile ranges. Frequency statistics were 
analysed using unpaired Man-Whitney U test (Median= 1.410, n= 17 IBM vs Median= 1.920, n=16 
H.C P= 0.4384). C) Frequency of γδ T cell subsets IBM (green symbols n=17) and H. C (green 
symbols n=16). Error bars indicate median ± interquartile ranges. Frequency statistics were 
conducted using Kruskal-Wallis ANOVA with Dunn’s post hoc test (P-value= 0.0013). Percentage 
of Vδ1+ (mean rank 62.97, n=17 IBM vs mean rank -2.529, n=16 H.C P= >0.9999). Percentage of 
Vδ2+ (mean rank 46.63, n=17 IBM vs mean rank 7.551, 17.3 n=16 H.C P= > 0.9999). and 
percentage of Vδ1- Vδ2- (mean rank 33.07 n=17 IBM vs mean rank 0.4333, n=15 H.C P= >0.9999). 
* P-value <0.05, **P-value <0.005, ***P-value <0.001 #P-value= not significant 
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3.8  The Frequency of γδ T cells and γδ Vδ subsets is the same between IBM and Healthy 
controls   
Figure 12B shows that the frequency of γδ T cells between IBM patients and healthy controls, 
mirror one another with no statistical significance identified (Median= 1.410, n= 17 IBM vs 
Median= 1.920, n=16 H.C P= 0.4384). It is evident from our results that the percentages of γδ T 
cells rarely exceed above the normal range of > 5% though percentages and/or whole numbers 
are expected to be reduced given the advanced age of the cohort. We do however, observe three 
IBM patients and two healthy controls with the expansion of γδ T cells above 4%. Figure 12C 
shows the frequency of γδ T cells subsets between IBM patients and H.C. The differences 
observed within the two cohorts mirror one another for percentages between the Vδ1+ subset 
(mean rank 62.97, n=17 IBM vs. mean rank -2.529, n=16 H.C P= >0.9999). Likewise, the 
comparison between IBM and H.C for the Vδ2+ subset again shows no statistical difference. 
Though considerable variance in frequency exists within both IBM patients and H.C Percentage 
of Vδ2+ (mean rank 46.63, n=17 IBM vs mean rank 7.551, 17.3 n=16 H.C P= > 0.9999). The Vδ1- 
Vδ2- subset shows the lowest frequency amongst all the γδ subsets (mean rank 33.07 n=17 IBM 
vs. mean rank 0.4333, n=15 H.C P= >0.9999). Although three IBM patients showed higher 
percentages (>30%). Healthy controls show one donor with higher than average percentages for 
this subset (>20%) though they are slightly less than those seen in IBM patients. A Kruskal-Wallis 
ANOVA was conducted for all groups and revealed a significant difference in the frequency 
between all γδ subsets (P=0.0013). It is therefore evident from these results that there is no 
difference between IBM patients and H.C for the frequency of γδ T cells and no differences within 
any of the three major γδ subsets. However, there is a statistical difference (P-value= 0.0013) 
between Vδ1+ and Vδ1- Vδ2- subsets for both IBM and HC.  
 

























Figure 13. Comparison between different memory subsets within the Vδ1+ and Vδ1- γδ T cells. 
A) Percentages of the Vδ1+ compartment memory subsets shown as median ± interquartile 
ranges between IBM (green symbols n=16 and H.C (blue symbols n=13). Frequency statistics 
were performed using Kruskal-Wallis ANOVA with Dunn’s multiple comparison test (P-
value=0.0001) (A) and Vδ1- (B) Percentages of the Vδ1- memory phenotypes between IBM 
patients (green symbols n=16) and H.C (blue symbols n=13) shown as median ± interquartile 
ranges. Frequency statistics were performed using Kruskal-Wallis ANOVA with Dunn’s multiple 
comparison test (P-value=0.0001). C) The comparison between effector memory (EM) and T-cell 
effector memory re-expressing CD45RA (TEMRA) phenotypes between Vδ1+ and Vδ1- subsets for 
C 
Vδ1- γδ T cells 
B 
E 
Vδ1+ γδ T cells 
A 
D 
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(green symbols n=) and H.C (blue symbols n=). Frequency statistics were calculated using paired 
Wilcoxon sum of ranks test  (IBM Vδ1+ EM vs. IBM Vδ1- EM P=0.0006) (HC Vδ1+ EM vs. HC Vδ1- 
EM P=0.0012) (IBM Vδ1+ TEMRA vs. IBM Vδ1- TEMRA P=0.0013) (IHC Vδ1+ TEMRA vs. HC Vδ1- TEMRA 
P=0.0012).  D) Expression of Ki67 expression shown as mean ±  SE on Vδ1+ effector memory 
(EM) and T-cell effector memory re-expressing CD45RA (TEMRA) phenotypes between IBM (green 
symbols n=6) and H.C (blue symbols n=12). Frequency statistics were achieved through one-way 
ANOVA with Bonferroni’s post-hoc comparison test (P-value= 0.0165). E) Expression of Ki67 
expression shown as mean ±  SE Vδ1-  effector memory (EM) and T-cell effector memory re-
expressing CD45RA (TEMRA) phenotypes between IBM (green symbols n=9) and H.C (blue symbols 
n=13) Frequency statistics was achieved through one-way ANOVA with Bonferroni’s post-hoc 
comparison test (P-value= 0.8981). * P-value <0.05, **P-value <0.005, ***P-value <0.001 #P-
value= not significant 
3.9  Vδ1+ cells have a higher frequency of TEMRA phenotype indicative of Late-differentiation 
in comparison to Vδ1- 
γδ T cells express features of both innate and adaptive immunity, the latter of which includes 
generation of memory phenotypes. To determine the phenotypes of the γδ T cell subsets, we 
utilized the markers CD45RA (CD45 isoform that show cell-type and differentiation-stage) and 
CCR7 (lymphoid homing receptor) to distinguish between stages of differentiation. i.e. naïve 
(CCR7+ CD45RA+), Central Memory (CM) (CCR7+ CD45RA-), Effector Memory (EM) (CCR7- 
CD45RA-) and effector memory re-expressing CD45RA (TEMRA) (CD45RA+ CCR7-). The frequency 
of each Vδ1+ and Vδ1- subset is given in Figure 12. A-B and are identified for both IBM and H.C.  
Within the Vδ1+ subset (figure 13 A and C) the predominate memory phenotype expressed 
between IBM and healthy cohorts are TEMRA cells with no significance between the groups 
indicated (IBM Vδ1+ EM vs. IBM Vδ1- EM P=0.0006) (HC Vδ1+ EM vs. HC Vδ1- EM P=0.0012) 
(IBM Vδ1+ TEMRA vs. IBM Vδ1- TEMRA P=0.0013) (IHC Vδ1+ TEMRA vs. HC Vδ1- TEMRA P=0.0012). The 
Vδ1- subset in comparison, shows that they predominantly express effector memory (EM) cells; 
however this subset of γδ T cells also shows a high variation within the TEMRA phenotype (figure 
13. B-C). Proliferation studies using Ki67 on the Vδ1+ memory subsets within IBM and healthy 
controls are shown in Figure 13D (one-way ANOVA P-value=0.0165). Here it is evident that the 
effector memory compartment there is a considerable difference between IBM and healthy 
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controls (Mean 205384, n=6 IBM vs. Mean 63982, n=12 H.C; P-value 0.0199). All comparisons 
between IBM and healthy controls within these memory subsets reveal insignificant results. It is 
uncertain as to what γδ T cells subset make up the Vδ1- compartment, though it is presumed 
that given Vγ9+Vδ2+ is the most prominent (as seen in figure 12C) subset that they would 
dominate this Vδ1- compartment. Here, the expression levels of Ki67 reveals no significant 
difference between IBM and H.C for all the subsets examined (one-way ANOVA P-value=0.8981). 
Overall, the Vδ1- compartment shows considerably higher expression levels of Ki67 amongst EM 

































Figure 14. Frequency and expression of CX3CR1 and CD57 in various γδ T cell subsets 
between IBM and Healthy Controls. A) Frequency of CX3CR1 in IBM (green symbols n=17) and 
healthy controls (blue symbols, n=13). Statistics were acquired using one-way ANOVA 
(frequency of CX3CR1) with Bonferroni’s post hoc test error bars indicate mean ±  SE (P-value= 
<0.0001)  B) Frequency of CD57 on γδ subsets in IBM (green symbols n=17) and healthy 
controls (blue symbols, n=13). Statistics were acquired using Kruskal-Wallis ANOVA with Dunn’s 
multiple comparison test. Error bars indicate median ±  interquartile ranges.  P=0.0043 C) 
Expression (geomean) of CX3CR1 in IBM (green symbols n=17) and healthy controls (blue 
symbols, n=13). one-way ANOVA with Bonferroni’s post hoc test, error bars indicate mean ±  
SE (P-value= 0.0001) D) Expression (geomean) of CD57 IBM (green symbols n=17) and healthy 
controls (blue symbols, n=13). one-way ANOVA (expression of CD57) with Bonferroni’s post 
hoc test error bars indicate mean ± SE (P-value= >0.9999). E) Representative histograms for 
CX3CR1 and CD57, respectively (donor 1). Dotted line indicates the relationship of all subsets 
to the histogram with the highest geomean * P-value <0.05, **P-value <0.005, ***P-value 
<0.001 #P-value= not significant 
 
3.10 CD57 and Cx3CR1 marker expression show γδ T cells are late-differentiated and homing 
to inflammatory locations.  
To explore the γδ subsets effector functions further, the frequency of surface markers CD57+ 
(marker of late-differentiation) and CX3CR1 (fractalkine receptor) were assessed within the Vδ1, 
Vγ9Vδ2 and Vδ1-Vδ2- subsets. Figure 14A shows the frequency of CX3CR1 between IBM and 
healthy controls (P-value= <0.0001). The Vδ1+ compartment shows high variation within IBM 
patients whereas variation in the healthy donors is less evident (mean 58.46, n=17 IBM; mean 
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variation in CX3CR1 with frequency between both IBM and H.C displaying no difference (mean 
98.02, n=17 IBM; mean 99.27, n=13 H.C; p-value= >0.9999). The Vδ1-Vδ2- compartment 
additionally shows considerable variation in both IBM and H.C with no significant difference 
observed (mean 41.07 n=17 IBM; mean 8.59, n=13 H.C; p-value= >0.9999). Lastly there was a 
higher significant difference observed between Vδ1+ and Vγ9+Vδ2+ compartments in IBM 
patients but not between Vδ1, and Vδ1-Vδ2- compartments (mean 58.46, n=17 Vδ1- mean 98.02, 
n=17 Vγ9+Vδ2+; P-value= < 0.0001); (mean 58.46, n=17 Vδ1+; mean 41.07, n=17 Vδ1-Vδ2-; p-
value=0.1631) respectively.  
CX3CR1 expression (Geomean) is shown in figure 14C and reveals the comparison between IBM 
and H.C (one-way ANOVA P-value=<0.0001). The comparison between IBM and H.C within the 
Vδ1+ compartment (mean 18435, n= 17 IBM; mean 25060, n=11 H.C; P-value=>0.9999). 
Similarly, there was greater variation in Vγ9+Vδ2+ compartment for IBM patients compared to 
H.C (mean 18435 n=17, mean 11665 n=16; P-value= 0.9532). Lastly, there was little variation 
amongst the Vδ2-Vδ2-compartment between IBM and healthy controls (mean 11665, n=16 IBM 
vs 11545, n=10 H.C; P-value =>0.9999).  Analysis between Vδ subsets within IBM patients reveals 
that there is significant difference between Vδ1- and Vγ9+Vδ2+ (mean 18435, n=17 IBM vs man 
52961 n=11 H.C; P-value= <0.0001), yet no conceivable difference is seen between Vδ1- and Vδ1-
Vδ2- compartments for IBM patients (mean 18435 n=17 vs mean 11665, n=16 H.C; P-value= 
0.9532).  
Figure 14B demonstrates the frequency of surface marker CD57 amongst the various Vδ subsets 
within IBM and healthy donors Analysis of variance using the Kruskal-Wallis test showed a 
significant difference amongst the Vδ subsets between IBM and healthy donors (P-value= 
0.0043). Within the Vδ1 subset, the frequency of CD57 is highly variable, with roughly 50% of 
the population showing high frequency (>50%) and the other 50% showing medium to low 
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frequency (<30%). In contrast, the healthy controls show CD57 frequency to be much less 
variability, with only one donor showing a higher frequency than average (>20%). The difference 
between IBM and healthy controls for CD57 frequency within Vδ1 is insignificant (mean rank 
48.79, n=17 IBM; mean rank 57.58, n=13 H.C; p-value= 0.4323). The Vγ9+Vδ2+ compartment 
again shows some considerable variation in CD57 frequency with the majority of IBM patients 
<20%, however one patient shows increased frequency (>30%) and three patients have 
exceedingly high frequency (>60%). Yet again, no signs of statistical significance are observed 
between IBM and H.C (mean rank 32.91, n=17 IBM; mean rank 26.38, n=13 HC; p-value= 
>0.9999). Notably, the frequency of CD57 in IBM patients within the Vδ1-Vδ2- subset again shows 
considerable variability with the majority of patients showing around 20% of cells expressing 
CD57 and no statistical difference is seen between IBM and H.C (mean rank 55, n=17 IBM; mean 
rank 52.27 n=13 H.C; p-value= >0.9999). Statistical analysis between IBM Vδ subsets yet again 
shows no statistical significance as evident from figure 14B. Figure 8D shows the expression of 
CD57  (shown as geomean) between IBM and healthy cohorts Vδ subsets. The expression of 
CD57 between IBM and H.C is consistent among all Vδ subsets and again, no statistical difference 
is noted between GD subsets (one-way ANOVA P= 0.6957).   
Figure 14E (1-2) shows the corresponding expression levels of CX3CR1 and CD57, respectively. 
The dotted line is a visual representation of where each Vδ subset sits in relation to the subset 
with the highest expression level.  As is evident from the histograms, there is considerable 
variation of CX3CR1 expression amongst the subsets while little variation in CD57 expression 
exists.   Here, our results show variable frequency and of CD57 in γδ T cell subsets (both IBM and 
H.C), yet CD57 is consistently expressed between IBM and H.C    similarly frequency of Cx3CR1 is 
variable Vδ1 subsets (IBM and H.C), yet the frequency is highest in the Vδ2+ subset. Conversely, 
the expression level of Cx3CR1 is again highest in the Vδ2+ subset.     



















Figure 15. Relationship between Frequencies of Vδ1+ CD27+/- and Vδ2+ subset CD27 +/- in 
IBM and Healthy Controls.  A) The frequency of Vδ1+ subsets from IBM patients (n=17) and 
healthy controls (n=13) was compared against their corresponding frequency of CD27+ or CD27- 
subsets. B) The frequency of Vδ1+ subsets from IBM patients (n=17) and healthy controls (n=13) 
was compared against their corresponding frequency of CD27+ or CD27- subsets. Statistical 
analysis was conducted using Spearman’s correlation for non-parametric data * P<0.05, ** 
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3.11 The percentage of Vδ1+ γδ T cells in IBM is correlated to the Frequency of CD27+/CD27- vs. 
Vδ1- CD27+ /CD27- 
γδ T cells exhibit a level of plasticity that can direct polarization and function. Plasticity has 
previously been shown to be mediated by the expression of tumor necrosis factor receptor 
family member CD27.(91, 92) The relationship between frequency of γδ T cell subsets (Vδ1+ and 
Vδ2+) with the frequency of CD27+/- expression was determined using Spearman’s correlation 
(Summarized in Table 5). We identified that the frequency of Vδ1+ was correlated with the 
frequency of CD27+/- in both IBM and H.C (figure 15A). For both IBM and H.C correlation 
indicates that as the frequency of Vδ1+ increases the frequency of CD27- cells also increases (r-
0.4951 P=0.0453 and r- 0.6264 P=0.0251 respectively). Conversely, the frequency of Vδ1+ is 
inversely proportional to the frequency of CD27+ as seen in both IBM and H.C (r=-0.4951 
P=0.0453 and r=-0.6264 P= 0.0251 respectively). In the Vδ2+ compartment however, the 
opposite effect is observed (figure 15B). In IBM patients the Vδ2+ subset is directly proportional 
to CD27+ (r=0.7181 **P=0.0016), whereas the CD27- population is inversely proportional to the 
frequency of Vδ2+ (r=-0.6863 **P=0.0031). Interestingly, no correlation is observed between 
Vδ2+ and CD27+/- in the healthy controls (CD27+ r=-0.1155 P=0.7056 and CD27- r=0.1320 
P=0.6653). These results thereby indicate that as the proportion of Vδ1+ γδ T cells increases so 
too does the percentage of CD27- cells. Again this trend is mirrored in both IBM and HC. In 
contrast, the Vδ2+ population showed a directly proportional relationship with CD27+ cells yet 
this trend is not seen in HC.   
Table 5. Spearman’s Correlation between Frequencies of Vδ1+ CD27+/- and Vδ2+ subset CD27 +/- 
  Vδ1+ CD27+ Vδ1+ CD27- Vδ2+ CD27+ Vδ2+ CD27- 
IBM 
 
r=-0.4951 P=0.0453 r-0.4951 
P=0.0453 
r=0.7181 **P=0.0016 r=-0.6863 **P=0.0031 
Healthy 
Control 
r=-0.6264 P= 0.0251 r- 0.6264 
P=0.0251 
r=-0.1155 P=0.7056  r=0.1320 P=0.6653  
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Table 6: comparison of CDR3 VB sequences between lymphocyte populations in two 
donors 
 Donor 15 Donor 16 
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Figure 16: Analysis of TCRβV and TCRβJ rearrangements and CDR3 sequences in peripheral 
blood and muscle homogenate T cells between two IBM donors. A) Comparison between the 
TCRβV and TCRβJ rearrangements in 1) peripheral blood CD4. 2) peripheral blood CD8, and 3) 
Muscle homogenate. 4) CDR3 sequence analysis in muscle homogenate. Muscle and PBMCs 
were taken from donor 14. B) Comparison between the TCRβV and TCRβJ rearrangements in 1) 
peripheral blood CD4. 2) peripheral blood CD8 and 3) Muscle homogenate. 4) CDR3 sequence 
analysis in muscle homogenate. Muscle and PBMCs were taken from donor 15. 
 
3.12 Clonality of muscle infiltrating T cells in comparison to peripheral blood T cells 
Two IBM patients (donors 14 and 15) were selected for bulk TCR sequencing analysis. Table 6 
shows the dominant CDR3 amino acid sequences found within peripheral blood CD4, CD8, and 
muscle samples between donors 14 and 15. Our analysis reveals the dominant CDR3 sequences 
contain a common terminal amino acid motif “NEQFF,” which can be seen in muscle samples 
from both donor 14 and 15 as well as in CD4 and CD8 populations for donor 14. Overall, donor 
14 shows CDR3 sequences with the common “NEQFF” terminal motif in all three populations 
(CD4/CD8 and muscle), whereas donor 15 only shows this dominant CDR3 sequence within the 
muscle sequence. Additionally, in donor 14 a secondary CDR3 sequence “CASSEPGQGGTEAFF” 
can be seen in the muscle and peripheral blood (CD4) population (Table 6), whereas in donor 15 
the CDR3 sequence “CASSEPFGAQHF” can be found in muscle and peripheral blood CD4 and CD8 
populations (Table 6).    
Circos spots showing dominant TCRβV and TCRβJ rearrangements are given in figure 16 A-B. 
βV25.1 with combined TCRβJ2.1, 2.7 and 1.1 segments are most dominant and are found in CD4, 
CD8 populations from both donors 14 and 15. Vβ25.1 with corresponding TCRβJ 2.7, 1.1 and 2.3 
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arrangements are also seen in donor 14 muscle samples; however, these arrangements are of 
small proportion while the dominant TCRβV segments shown as TCRβV15 corresponding to 
TCRβJ 2.1 (figure 16 A. 3). Likewise, the most dominant TCR βV segment seen in the muscle 
sample from donor 15 was TCR BV4.1 (figure 16 B. 3) however this TCRβV chain most commonly 
occurring TCRβJ pair was TCRβJ 2.1 and is the most common TCRβJ segment throughout the 
various populations and donors (figure 16 A. 1,2,3 and Figure 16 B. 1,2,3 ). CDR3β Circos spots 
were given for muscle samples only (figure 16 A. 4 and Figure 16 B. 4). The Colours correspond 
to the frequency of each specific CDR3β sequence. Here both donors have a dominant CDR3 
sequence containing the terminal “NEQFF” motif. Overall, the TCR sequence analysis of 
peripheral blood CD4 and CD8 and muscle homogenate reveals common TCRβV and TCRβJ 
rearrangements and CDR3 sequences and/or terminal motifs across the three samples and 
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Chapter 4: Discussion 
A lymphoproliferative disorder of CD8 T cell Large granular lymphocytes was recently found to 
be associated in an American cohort of IBM patients.(78)  Similarly, this same association can be 
seen here in an Australian cohort, stipulating that T-LGL leukaemia may be contributing to the 
pathogenesis of IBM. Expansions of CD8+ T cells expressing a late-differentiated phenotype 
characterised by CD57 upregulation and CD5- forms the basis upon which we identify T-LGL 
populations. Complete diagnosis for T-LGL leukaemia is ambiguously defined; however, a 
combination of parameters can provide diagnostically useful information. i.e. T-LGL count of > 
0.4x109/L blood, altered CD4/CD8 ratio <1.5, along with phenotypical characteristics of increased 
frequency of CD8 T cells upregulating CD57 (> 15% of the total T lymphocyte population), a 
decrease in CD5 expression and an increased expression of Natural Killer cell receptors such as 
CD94 and variable expression of CD56. Currently, our cohort of IBM patients demonstrates 32% 
(8/25) show phenotypical characteristics consistent with a diagnosis of TLGL leukaemia. 
However, 16% (4/25) IBM patients show increasing expansions of T-LGLs (>0.4x109/L blood), yet 
do not display phenotypical characteristics or altered CD4/CD8 ratios. Unexpectedly our analysis 
has detected that a significant proportion (17%) of our healthy controls that were phenotypically 
indistinguishable from T-LGL leukaemia positive patients (donor 34, 36, 41). Indeed 
poly/oligoclonal expansion of T-LGLs amongst healthy aged individuals have been described in 
other reports,(93) and indicates that expansion of T-LGLs may be a commonality among ageing 
population however, continued insult by CD8+ T cells as a result of chronic inflammation or 
immune-associated diseases may transform these cells toward a dysfunctional state and 
promotion towards leukaemia.(78) Conversely, diagnosis T-LGL leukaemia requires clonal 
expansion of T-LGLs amidst an appropriate clinical context.(79-81) The absence of which, seen in 
healthy controls, may eliminate these donors as T-LGL leukaemia positive candidates and the 
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expansion and phenotypic changes seen in these patients may be a result of ageing. 
Alternatively, some authors have proposed that T-LGL expansion consists of a spectrum of 
disorders that can be dichotomized based on clinical symptoms, phenotype and clonality.(81, 94, 
95) Monoclonal proliferation of T-LGLs in conjunction with clinical disease and phenotypic 
changes directs a diagnosis of T-LGL leukaemia; whereas poly or oligoclonal expansion of T-LGLs 
decrees a diagnosis of reactive T-LGL expansions, though these expansions are not necessarily 
neoplastic.(79) The vast level of phenotypical heterogenicity observed within our IBM and healthy 
cohorts confer what has been suggested previously, yet without clonal studies, these expansions 
of T-LGL remain indeterminant. Regardless, it is evident from our analysis that T-LGL 
proliferations (neoplastic or reactive) are nonetheless associated with IBM and is also found with 
increasing prevalence in aged individuals.   
Figure 17: Dichotomy of T-LGL Proliferations. Adapted from Lamy, T et al. 2016 (81)  
The association between age and T-LGL count in 1L blood displays insignificant results suggesting 
that age isn’t a predictor for the development of T-LGL leukaemia. In reference to this, though, 
IBM is notoriously difficult to diagnose, given that symptoms are non-specific and slowly 
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progressive. Likewise, the diagnosis of T-LGL leukaemia is often delayed due to the indolent 
nature of this disorder.(79)  Thus, we cannot say for certain that advancing age is not a predictor 
for the development of leukaemia, though this may open new avenues for future longitudinal 
studies to investigate. Likewise, Greenberg et al. investigated the duration of IBM symptoms and 
muscle strength in IBM patients with T-LGL expansion and IBM without T-LGL expansion and 
showed that IBM patients with expanded T-LGLs had more severe muscle weakness, suggesting 
that T-LGL leukaemia may worsen IBM symptoms.(78) 
All T-LGL leukaemia cases (IBM and H.C) showed aberrant expression of cell surface markers that 
could be identified by flow cytometry. Surface markers that were examined included CD57, CD5, 
CD94, CD56, and KLRG1 in addition to intracellular recognition of proliferation-associated 
marker Ki67. Our analysis reveals that 8/8 of IBM T-LGL + patients show an increased frequency 
of CD8+ CD57+ cells (>30%), and an increase in CD8+ CD5- (>1%), whereas IBM patients displayed 
considerable variability within the frequency of CD94 (>8% ) and CD56 (>2%). Increased 
expression of CD57 present on T lymphocytes is indicative of late-differentiation and is 
postulated to be the result of chronic antigen stimulation.(76)  Previously, CD57 was used to 
define senescence and is used interchangeably with clonal exhaustion/ proliferative inability 
amongst T cell populations.(76, 96)  Shortened telomere length, reduced telomerase activity and 
reduced expression of cell-cycle genes contribute to this theory of replicative senescence.(76, 96) 
Amidst an appropriate cytokine milieu; however, CD8+ CD57+ cells transiently up-regulates 
telomerase activity suggesting that these cells still retain some proliferative potential.(97)  Thus 
CD8+ CD57+ cells are now more appropriately assigned as a marker of late-differentiated cells 
with proliferative capabilities and high cytotoxic potential.(76)  Our study has subsequently 
affirmed (using Ki67) that CD8+ CD57+ cells are indeed capable of proliferation and that the 
presence of CD57 confers the alternative paradigm that these cells are late differentiated though 
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not necessarily senescent.  Furthermore, the frequency of Ki67 is highest within IBM T-LGL + 
subjects across all CD5CD57 populations, which is most likely due to T-LGLs ability to acquire 
mutations that enable continued proliferation.(81) Moreover, increased expression of CD57 is a 
known associate of chronic inflammatory processes including autoimmunity, and the 
reactivation of persistent viruses such as CMV, the latter of which is shown to drive the 
oligoclonal expansion of CD8+ CD57+ T cells. (98) CD8+CD57+ T cells are effector memory cells that 
produce IFN-y and TNFα upon stimulation.(76) These pro-inflammatory cytokines would have 
considerable implications on the disease severity within IBM T-LGL positive patients.   
Killer cell lectin-like receptor G1 (KLRG1) is an inhibitory co-receptor expressed by activated T 
lymphocyte and NK cells (89)  and includes an immune receptor tyrosine-based inhibitory motif 
(ITIM) situated within its cytoplasmic domain.(87) The effects produced by this receptor mount 
interference with proliferation signaling upon binding to its ligand E-Cadherin.(99)   Furthermore, 
following previous reports, KLRG1 is shown to be associated with ageing and differentiation 
status, with more than 90% of CD8+ T cells expressing KLRG1 found in individuals >65 years; the 
highest proportion of which is seen on memory cells and late-differentiated memory cells.(87)  
KLRG1 was a late addition to our analysis; thus many of our T-LGL + IBM patients were not 
assessed using this marker; consequently, characterisation of KLRG1 expression within this 
cohort is limited. The few IBM + T-LGL patients that were assessed using KLRG1 showed the 
frequency of this marker increases according to CD8+ differentiation status, with the CD5-CD57+ 
population having the highest frequency of KLRG1 (figure 11D). Furthermore, no conceivable 
difference was evident between IBM patients and HC for the frequency of KLRG1 (Figure 11B-F). 
This reinforces the premise that increased KLRG1 expression is constituted upon cells with late-
differentiated status and is highly prevalent within an ageing population. Likewise, KLRG1 is 
highly expressed in cells specific for epitopes against latent CMV and EBV (89) further conforming 
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to the idea that chronic inflammatory conditions are key drivers of highly differentiated 
phenotypes. 
In Healthy aged individuals, expression of cell surface marker CD5 is present and adequately 
maintained. CD5 is a negative TCR regulator resulting in an increased threshold needed for TCR-
antigen stimulation.(86)  The loss of CD5 as seen in our cohort of T-LGL positive patients and few 
healthy controls, would likely result in heightened T cell responses upon antigenic stimulation. 
Given this, we can stipulate that T-LGL leukaemia may promote autoreactive T cell responses or 
at the very least, would increase symptom severity resulting in worsened disease outcomes in 
IBM patients. The gain of CD57 is shown to precede the loss of CD5 (figure 5B); thus, persistent 
inflammatory responses that drive CD57 upregulation can subsequently result in the loss of CD5 
thereby leading to dysregulated TCR responses.  
CD94 is a heterodimer that consists of several innate-like families of C-type lectin receptors, 
predominantly expressed on natural killer (NK) cells and a few subsets of CD8+ T cells and γδ T 
cells and is documented to be increased in T-LGL leukaemia.(78, 79, 100)  Our data show that CD94 
expression is variable amongst the IBM T-LGL cohort with only 3/8 patients showing increased 
frequency above the average (8%), in contrast only 1/17 IBM T-LGL negative patient showed 
increased frequency, whereas all healthy donors that were T-LGL positive (3/17) showed 
increased frequency (supplementary figure 1. CD94 stimulates or inhibits NK cells and T 
lymphocyte cytotoxicity depending on which NKG2 isoform is expressed.(100) CD94/NKG2A is the 
inhibitory isoform whose functions include regulating effector function through blocking 
cytotoxicity, although they have also been shown to regulate NK and T cell survival 
mechanisms.(100) CD94/NKG2C, on the other hand, has been found on activated T cells and can 
thereby promote cytotoxic functions and contributing to innate -immunity. Deciphering 
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between activating or inhibiting forms of CD94/NKG2, however,  is not achievable through CD94 
antibody use alone; thus, we cannot say for certain what isoform T-LGLs are expressing.  
The upregulation of neural cell adhesion molecule (NCAM) CD56 on T-LGLs is considered to be a 
poor prognostic feature for this leukaemia and is correlated to increases in STAT5b mutations.(79)  
Likewise, CD56 upregulation correlates to increased IFN-γ production indicative of increased 
cytotoxic function.(78, 101)   CD56 upregulation is seen in 25% of IBM T-LGL positive patients yet is 
not observed within IBM T-LGL- patients or healthy donors. The acquisition of both CD94 and 
CD56 correlates to a heightened status of dysregulation and the promotion of cytotoxic 
responses. Overall, abnormal expression of surface markers leads to the belief that T-Cell Large 
Granular Lymphocytes may be augmenting heightened inflammatory responses thereby 
increasing disease severity amongst IBM patients.(78)    
Conversely, several studies have reported that a definitive diagnosis of LGL leukaemia requires 
evidence of clonal expansion in T-LGL populations.(78-80) These studies have utilised TCR 
sequencing techniques to assess the TCR-γ chain. Such methods have yielded results suggesting 
a restricted diversity within the T-LGL TCR repertoire.(78, 79). It is, however, unclear as to the 
reasons for analysing the TCR-γ chain, whereas the majority of the T-LGLs possess the TCRαβ 
phenotype.(80, 81) As such, we did not assess for clonality within our cohort of T-LGL positive 
patients which represents a considerable limitation in the present study. However, collaborative 
efforts are in place with preliminary results indicative of oligoclonal T-LGL populations 
(unpublished).   
Overall, T-LGL leukaemia is a late-differentiated lymphoproliferative disorder that has shown to 
accumulate in 32% of IBM patients and 17% of H.C. Immunophenotyping of these cells provides 
considerable diagnostic value yet reveals significant individual heterogenicity within the 
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phenotype of these cells that explains the ambiguous diagnosis of T-LGL leukaemia. Moreover, 
the gain of aberrant cell surface markers, including CD57+, CD5- CD94+ CD56+ and KLRG1+ T-LGLs, 
translates to potent effector functions and reinforces the theory that T-LGL leukaemia is more 
of a chronic illness as opposed to a neoplastic disease that is likely precipitating autoimmunity. 
Furthermore, recent reports suggested that T-LGL leukaemia likely impacts the severity of IBM 
symptoms, particularly muscle weakness.(78)   We can, therefore, appreciate how T-LGL 
leukaemia present as an additional burden and would have likely implications for the diagnosis, 
prognosis, management and future treatments of IBM. Future studies may, therefore, 
investigate how these dysregulated cells contribute to the burden of disease in IBM.  
T cells expressing the unconventional γδ T cell receptor possess characteristics of both innate 
and adaptive immunity and have been shown to confer important ant-viral protection.(59)   Here 
in this study, we have affirmed that the percentage of γδ T cells is slightly reduced amongst IBM 
patients (median= 1.4%) and healthy age-matched controls (median= 1.9%), as is consistent with 
previous studies that show advancing age leads to decline in γδ T cell population.(77)    
Nonetheless, 23% IBM and 12.5% healthy controls show increased percentages  (>4.0%) of γδ T 
cells. The decline in absolute number or frequency of γδ T cell has major perturbations for the 
functionality of immune-mediated responses against novel pathogens.(77)   Our analysis has 
further revealed that the repertoire of γδ T cell subsets (Vδ1, Vγ9+Vδ2+ and Vδ1-Vδ2- ) is altered, 
with an increased frequency Vδ1, (Figure 12C). Furthermore, the frequencies of all γδ T cell 
subsets in IBM and H.C cohorts parallel one another, suggesting that change observed is the 
likely result of increasing age. Importantly, Vδ1 is a minor subset within the peripheral circulation 
(62) thus its prevalence shown in this study (figure 12C) is suggestive of a shifted repertoire that 
is most likely associated with the effects of ageing.   
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Chronic immune conditions or viral responses promote the development of effector and effector 
memory T cells which is most prominent in CD4/CD8 T cell lineages.(77) Likewise, γδ T cell Vδ 
repertoires are subjected to memory/ effector memory expansion under chronic antigenic 
stimulation.(62, 102) The Vδ1 (in IBM and H.C, figure 13A) were composed mostly of late-
differentiated effector memory re-expressing CD45RA (TEMRA) phenotype (CD45RA+ CCR7- CD27-
) whereas the Vδ1- cells are mostly effector memory cells  (CD45-CCR7- CD27+) and few exhibit 
TEMRA phenotypes (CD45RA+ CCR7-) (figure 12B). Notably, the Vδ2+ compartment in IBM patients 
displayed an increased correlation with CD27+ that was not observed within the healthy donors 
(figure 15B). There is a level of plasticity within the γδ T cell that which is mitigated in response 
to certain cytokine stimuli and can direct the polarisation of γδ T cells towards a cytotoxic 
response or Th1-like, Th2-like and Treg-like or Th17-like effector functions.(67, 103-105)   γδ T cell 
capable of producing IL-17 and/or IFN-y has prompted an investigation into their functional role 
in immune-homeostasis and disease. γδ T cell commitment to production of IFN- y or IL-17 is 
pre-determined during thymic development and is constituted upon expression of CD27.(91, 92)   
Cells will delineate into CD27- cells producing IL-17, whereas IFN-y production is limited to CD27+ 
cells.(92) Furthermore, the increased proportion of Vδ1 cells expressing CD27- observed within 
IBM patients and healthy controls may elicit polarisation of this subset towards a Th-17-like 
function.  Likewise, Vγ9+Vδ2+ production of CD27+ that is evident in IBM but not in healthy 
controls may elicit polarisation of this subset towards a Th1-like, IFN- y secreting response and 
thereby promote IBM symptomatology.   
To examine the concept that chronic immune conditions drive differentiation within the memory 
γδ T cell subsets, cell surface marker CD57 (a marker for late differentiation) was examined. Our 
observations show markable heterogenicity in CD57 frequency amongst the γδ T cell subsets 
that are reflected between IBM patients and healthy subjects. Expression (geomean) of CD57, 
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on the other hand, remains constant between all subsets and donor cohorts, although the 
frequency is notably increased in 7/17 (41%) Vδ1 IBM patients. As previously stated, CD57 is 
characteristic of late-stage differentiation which may/may not be reminiscent of senescence or 
clonal exhaustion. To evaluate the capacity of memory subset proliferation further, KI67 was 
utilized for determining the replicative nature of these populations. Our analysis reveals a lower 
expression level of Ki67 in the Vδ1 TEM and TEMRA populations, whereas the Vδ1- compartment 
shows considerably higher expression levels of Ki67 amongst TEM and TEMRA phenotypes (Figure 
13 D-E respectively). The lower expression level of KI67 observed within the Vδ1+ compartment 
supports the notion that chronic antigen stimulation that drives their expansion may also result 
in exhaustion within this subset.   
Moreover, considerable inter-individual differences are observed within the Vδ1+ subset for 
CX3CR1 (fraktaline receptor), an endothelial homing chemokine, heightened expression of 
which, is suggestive of migration to inflammatory locations and peripheral 
immunosurveillance.(59, 62) Interestingly, it was the Vγ9+Vδ2+ compartment that displayed the 
highest frequency and expression levels for CX3CR1. Yet again, IBM patients mirror H.C 
suggesting that the frequency of this marker is not unique to IBM patients. Previous reports 
indicate that Vγ9+Vδ2+ cells are more innate-like in structure yet possess characteristics of 
adaptive immunity.(59) 
Our findings have exposed that selective expansion of Vδ1 cells amongst elderly individuals is 
increased within both IBM and healthy subjects. This suggests that changes observed within 
these cohorts are due to the advancement of age rather than IBM pathology. Increased 
expression of Vδ1, in addition to the accumulation of effector memory (TEM and TEMRA) 
populations, with reduced proliferative abilities and increased frequency of CD27-, CD57 and 
CX3CR1 are suggestive of strong adaptive immunosurveillance. Vδ1 anti-viral immunity against 
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CMV antigens has been previously reported as a potential candidate driving these responses.(68)  
CMV infection is generally benign in healthy immunocompetent individuals; however ageing and 
advancement of immunosenescence are perceived to be a key determinant in CMV 
reactivation.(68, 75)  Over time, CMV carriage has been shown to drive the effector memory T cell 
pool in CD4+/CD8+ T cells and recently been described for γδ T cells also.(75)   
In summation, ageing has a significant impact on the immune system, most notably resulting in 
the decline within the T lymphocyte populations. This phenomenon has been linked to the 
increased susceptibility toward the development of infection, cancers and autoimmune 
diseases.  Autoimmune diseases such as IBM are chronic and therefore taxing on the host 
immune defenses and are likely contributing to γδ T cell differentiation and immunosenescence. 
Therefore, changes associated with the ageing process will likely contribute to IBM diseases’ 
pathogenesis. Chronic inflammation and immunosenescence may also enable opportunistic 
viruses such as CMV to reactivate from their dormant state and contribute to worsened disease 
outcomes amongst the elderly.  Furthermore, CMV seropositivity is known to accentuate the 
Vδ1 compartment and promote effector memory (TEM) and differentiated effector memory cells 
(TEMRA). At present, no strong correlation has been identified between viral infections and the 
pathogenesis of IBM. However, given the evidence in favour of γδ T cell immunity against CMV, 
it may be of interest for future studies to investigate if latent viral infections such as CMV become 
reactivated within IBM patients and thereby contribute to the burden of disease.  
Previous attempts to characterize the TCR repertoire within IBM patients' muscle infiltrating T 
cells were shown to contain substantial limitations(55, 56) and has prompted the need to re-
evaluate the TCR using new and advanced techniques. Analysis of the  Vβ repertoire using Next 
Generation Sequencing (NGS)  demonstrates that CD4, CD8 and muscle infiltrating lymphocyte 
populations display an oligoclonal pattern of expansion (figure 16). Here both donors have a 
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dominant CDR3 sequence containing the terminal “NEQFF” motif that can be seen in peripheral 
blood CD4/CD8 populations and muscle homogenate. Additionally, our analysis reveals common 
TCRβV and TCRβJ rearrangements and CDR3 sequences and/or terminal motifs are shared across 
the three samples and between donors. Our results are consistent with previous observations 
by Bender et al. (55) who also demonstrated that autoinvasive muscle T cells were 
mono/oligoclonal.  However, it is important to disclose that our flow cytometry analysis of 
separated CD4 and CD8 population revealed a considerable portion of the CD8 population was 
contaminated with CD4s thus we cannot say for certain that the dominant Vβ genes and CDR3 
sequences are truly seen in CD8 or if they are  CD4.  
Moreover, dominant muscle infiltrating clones were also detected in CD4 and CD8 populations 
isolated from peripheral blood. This suggests these clones are not resident muscle T cells but are 
rather migrating from the periphery to the inflamed muscle.  The next step will consist of 
evaluating whether the clones found expanded in the muscles are CD8+ T-LGLs. We can do this 
one of two ways: 1) use CITE-Sequencing on total muscle T cells or 2) presorting muscle-isolated 
T cells into T-LGL negative vs. positive subsets before (NSG) sequencing.  If these dominant clones 
turn out to be T-LGLs, it will lead to the possibility of targeted drug therapies.   
4.1  Conclusion and Perspectives 
IBM is a progressive inflammatory muscle disease of autoimmune origin that primarily affects 
people over the age of 45. It is known that ageing negatively affects immune system functions 
and is a major factor towards immunosenescence. Likewise, chronic immune conditions (such as 
autoimmunity) and latent viral infections are key drivers of memory and effector memory T cell 
expansion. These cells generally have potent cytotoxic potential and decreased proliferation 
abilities. Additionally, chronic antigenic stimulation is hypothesised to result in dysregulated 
immune functions and the promotion of malignancies. 
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We can, therefore, appreciate how chronic autoimmune diseases such as IBM may lead to the 
development of T-LGL leukaemia. Given the high proportion of T-LGL within IBM patients, we 
may, therefore, speculate that these cells will contribute towards increased disease severity and 
worsened patient outcomes. This study has also provided further insight and reinforcement of 
current literature surrounding the immunobiology of Vδ1 and Vδ2 γδ T cell; with respects to 
their phenotype, effector function, and plasticity and how these features are altered during 
advancing age. Further studies into the disease burden caused by T-LGL leukaemia and γδ T cell 
immunity against chronic latent viruses, will likely lead to the development of novel treatment 
options to help reduce symptom severity and morbidity amongst IBM sufferers. Our study has 
also provided preliminary insights into the clonality of muscle infiltrating T cells, with the 
identification of common CDR3 sequences motifs that are maintained between donors and 
lymphocyte populations. The next stage in understanding the clonality of these T cell populations 
will involve utilizing new technologies such as Cite-seq to decipher if the dominant clones 
identified during our preliminary study are T-LGL populations.  This would likely lead to 
innovative treatment options for IBM patients.  
4.2  Key Messages: 
1. T-LGL leukaemia is associated with 32% of IBM patients, and 17% of our healthy 
controls  
2. Flow cytometry analysis of T-LGLs shows considerable heterogenicity amongst 
subjects, although the majority display a late-differentiated phenotype characterised 
by CD3+ TCRαβ CD8+ CD57+ CD5- KLRG1+ with variable expression of CD94+ and CD56+.   
3. No clonal analysis was conducted for T-LGLs so distinguishing between poly/oligoclonal 
(reactive) T-LGL and monoclonal (neoplastic) T-LGL was unachievable  
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4. Chronic antigenic stimulation is postulated as the main driver in the development of T-
LGL leukaemia  
5. IBM T-LGL+ patients show greater proliferation potential (based on frequencies of 
Ki67) within all CD5CD57 populations compared to other cohorts and are indicative of 
a dysregulated lymphoproliferative disorder.  
6. T-LGL leukaemia is likely to worsen disease symptoms leading to increased suffrage 
amongst IBM patients  
7. 23% of IBM patients and 12.5% of healthy controls show increased frequencies of γδ T 
cell (>4%), and both displays increased Vδ1 frequency  
8. Both Vδ1 cells in IBM and healthy controls display a higher proportion of TEMRA cells 
that show reduced expression of Ki67 suggesting these populations are nearing 
senescence. The Vδ2 cell has a higher proportion of TEM and has a slightly higher 
expression of Ki67 indicating they still retain some proliferative ability.  
9.  Vδ1 cells show variability within frequencies of (fraktaline receptor) CX3CR1 and CD57, 
whereas Vδ2 displays the highest frequencies and least variability of CX3CR1 yet CD57 
frequency was variable.  
10. Correlation analysis reveals that as the proportion of Vδ1 increases, so too does CD27- 
cells and is paralleled between IBM and HC. In comparison, an increase in Vδ2 shows 
an increase in CD27+ that was not seen in healthy controls.  
11. Both IBM donors have a dominant CDR3 sequence containing the terminal “NEQFF” 
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Supplementary Figure 1: Number of CD4 and CD8 cells/ μl between IBM and Healthy controls 
and Frequency of CD94 and CD56 between IBM +T-LGL, IBM no T-LGL and Healthy controls. A) 
number of CD4 cells/ μl between IBM (green symbols n=25) and healthy controls (blue symbols 
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Unpaired Mann-Whitney u test (Median 618.0, n=25 IBM vs Median 804.0, n=17, H.C; P-
value=0.1056). B) number of CD8 cells/ μl between IBM (green symbols n=25) and healthy 
controls (blue symbols n=17). Error bars indicate median ± interquartile ranges. Statistical 
analysis was performed using Unpaired Mann-Whitney u test (Median 350.0, n=25, n=25 IBM vs 
Median 303.0, n=17, n=17, H.C; P-value=0.1056).  C) frequency of CD94 cell surface expression 
between IBM T-LGL + (green symbols n=8) IBM no T-LGL (red symbols, n=17) and healthy controls 
(blue symbols, n=17). Error bars indicate median ± interquartile ranges. Statistics were analysed 
using Kruskal-Wallis ANOVA (P=0.0266) with Dunn’s post hoc multiple comparisons test between 
cohorts (mean rank 29.5,n=8 IBM +T-LGL vs mean rank 15.94, n=17 IBM; P-value=0.0199) (mean 
rank 29.5,n=8 IBM +T-LGL vs mean rank 23.99,n= 17 H.C; P-value=0.4761). D) Frequency of CD56 
cell surface expression between IBM T-LGL + (green symbols n=8) IBM no T-LGL (red symbols, 
n=17) and healthy controls (blue symbols, n=17). Error bars indicate median ± interquartile 
ranges. Statistics were analysed using Kruskal-Wallis ANOVA (P=0.3982) with Dunn’s post hoc 
multiple comparisons test between cohorts (mean rank 24.3,n=8 IBM +T-LGL vs mean rank 
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